List of phenyltropanes#η6-3β-(transition metal complexed phenyl)tropanes
{{Short description|none}}
{{cleanup|reason=unencyclopediac details in tables: compound-numbers specific to certain references ("7e", for example)|date=May 2019}}
Phenyltropanes (PTs) are a family of chemical compounds originally derived from structural modification of cocaine. The main feature differentiating phenyltropanes from cocaine is that they lack the ester functionality at the 3-position terminating in the benzene; thus, the phenyl is attached direct to the tropane skeleton (hence the name "phenyl"-tropane) with no further spacer that the cocaine benzoyloxy provided. The original purpose of phenyltropane-related research was to extirpate the cardiotoxicity inherent in the local anesthetic "numbing" capability of cocaine (which stems from the methylated benzoate ester being essential to cocaine's blockage of sodium channels, and which causes topical anesthesia) while retaining stimulant function.{{efn| ←[https://www.erowid.org/archive/rhodium/pdf/cocaineanalogs.pdf#5 Page #929 (5th page of article)] § II}}
Phenyltropane compounds present promising avenues of research into therapeutic applications, particularly in regard to addiction treatment. These compounds' uses vary depending on their construction and structure-activity relationship ranging from the treating of cocaine dependency to understanding the dopamine reward system in the human brain to treating Alzheimer's and Parkinson's diseases. (Since 2008 there have been continual additions to the list and enumerations of the plethora of types of chemicals that fall into the category of this substance profile.[http://v3.espacenet.com/publicationDetails/originalDocument?CC=US&NR=2008153870A1&KC=A1&FT=D&date=20080626&DB=EPODOC&locale=en_gb U.S. Patent Application Publication # US 2008/0153870 A1] M. J. Kuhar, et al. Jun. 26, 2008. Research Triangle Institute.) Certain phenyltropanes can even be used as a smoking cessation aid (cf. RTI-29). Many of the compounds were first elucidated in published material by the Research Triangle Institute and are thus named with "RTI" serial-numbers (in this case the long form is either RTI-COC-n, for 'cocaine' "analog", or specifically RTI-4229-n of the subsequent numbers given below in this article){{efn|Many of the RTI phenyltropanes are "RTI-4229-×××" where × is the specific phenyltropane code number.
—
e.g. RTI-55 is in-fact RTI-4229-55 but given below as simply RTI-55 for the sake of simplicity in shorthand (following as is done in the literature itself) as the subject matter in context is wholly within the scope of the phenyltropane coded category herein. Sometimes (more rarely) it is given as RTI-COC-××× for "cocaine derivative."
—
Worth mentioning in notation as to explain that other compounds entirely unrelated can be found with the same "RTI-×××" short-numbered assignation. Therefore it is to be expected that within different contexts a compound or chemical of the same name very possibly could be in reference to an entirely other substance of another chemical series non-analogous to those in this topic.}} Similarly, a number of others are named for Sterling-Winthrop pharmaceuticals ("WIN" serial-numbers) and Wake Forest University ("WF" serial-numbers). The following includes many of the phenyltropane class of drugs that have been made and studied.
File:Phenyltropane.gif|3D rendering of troparil; which comprises a privileged scaffold of among the phenyltropane class of compounds.
File:Troparil structure.png|Troparil structure: cf. {{US patent|5,496,953}}
2-Carboxymethyl esters (phenyl-methyl[[ecgonine]]s)
File:Epibati-tropane.svg|Epibatropane{{US patent|6479509}} containing a nitrogen heteroatom in the benzene ring formation.
File:Tamagnan.png|Tamagnan:{{cite journal | doi = 10.1016/j.bmcl.2004.12.014 | title=Synthesis and monoamine transporter affinity of new 2β-carbomethoxy-3β-[4-(substituted thiophenyl)]phenyltropanes: discovery of a selective SERT antagonist with picomolar potency | journal=Bioorganic & Medicinal Chemistry| date=2005 | volume=15 | issue=4 | pages=1131–1133 | first=Gilles | last=Tamagnan | pmid=15686927}} SSRI, SERT = 17(pM) = 10 times the strength of paroxetine for 5HT.
File:RTI-298.svg|RTI-298
File:RTI-11W.svg|(4′-)para-cis-propenyl-phenyl-methylecgonine. A rare SDRI compound with negligible NET affinity (>2,800.0nM displacement value for NET ligand) that retains significant DAT & SERT (15.0nM & 7.1nM) affinity.
File:Carroll 15.svg|C2-C3 unsaturated (non-isomeric, neither α nor β orientated) 2-naphthyl-tropane
File:Carroll 13.svg|1-naphthyl-tropane in its usual (comparably non-standard) boat formation of its tropane ring.
Like cocaine, phenyltropanes are considered a 'typical' or 'classical' (i.e. "cocaine-like") DAT re-uptake pump ligands in that they stabilize an "open-to-out" conformation on the dopamine transporter; despite the extreme similarity to phenyltropanes, benztropine and others are in suchwise not considered "cocaine-like" and are instead considered atypical inhibitors insofar as they stabilize what is considered a more inward-facing (closed-to-out) conformational state.{{cite journal | date = Jul 2013 | title = Nonclassical Pharmacology of the Dopamine Transporter: Atypical Inhibitors, Allosteric Modulators, and Partial Substrates| journal = J Pharmacol Exp Ther | volume = 346 | issue = 1| pages = 2–10 Fig. 1 | doi = 10.1124/jpet.111.191056 | pmc=3684841 | pmid=23568856 | last1 = Schmitt| first1 = K. C.| last2 = Rothman| first2 = R. B.| last3 = Reith| first3 = M. E.}}
Considering the differences between PTs and cocaine: the difference in the length of the benzoyloxy and the phenyl linkage contrasted between cocaine and phenyltropanes makes for a shorter distance between the centroid of the aromatic benzene and the bridge nitrogen of the tropane in the latter PTs. This distance being on a scale of 5.6 Å for phenyltropanes and 7.7 Å for cocaine or analogs with the benzoyloxy intact.{{efn| ←[https://www.erowid.org/archive/rhodium/pdf/cocaineanalogs.pdf#46 Page #970 (46th page of article)] §B, 10th line}} The manner in which this sets phenyltropanes into the binding pocket at MAT is postulated as one possible explanation to account for PTs increased behavioral stimulation profile over cocaine.{{efn|{{Cite journal|url=https://www.erowid.org/archive/rhodium/pdf/cocaineanalogs.pdf|doi=10.1002/chin.200020238|title=Chem Inform Abstract: Chemistry, Design, and Structure-Activity Relationship of Cocaine Antagonists|journal=ChemInform|volume=31|issue=20|pages=no|year=2000|last1=Singh|first1=Satendra}} [https://www.scribd.com/doc/77191354/Satendra-Singh-Chemistry-Design-and-Structure-Activity-Relationship-of-Cocaine-Antagonists Mirror hotlink.] ←[https://www.erowid.org/archive/rhodium/pdf/cocaineanalogs.pdf#47 Page #971 (47th page of article)] 1st ¶, 10th line}}
Blank spacings within tables for omitted data use "no data", "?", "-" or "—" interchangeably.
{{sort under}}
class="wikitable sortable sort-under"
|+2β-carbmethoxy-3β-(4′-substituted phenyl)tropanes ({{IC50}} values) ! Structure x100px ! Short Name ! R (para-substitution) ! DA ! 5HT ! NE ! selectivity ! selectivity | |||||||
cocaine (benzoyloxytropane) | H | 102 ± 12 241 ± 18ɑ | 1045 ± 89 112 ± 2b | 3298 ± 293 160 ± 15c | 10.2 0.5d | 32.3 0.7e | |
x100px | (para-hydrogen)phenyltropane WIN 35,065-2 (β-CPT{{efn|Beta (i.e. 2,3 Rectus)-Carbmethoxy-Phenyl-Tropane}}) Troparil 11a | H | 23 ± 5.0 49.8 ± 2.2ɑ | 1962 ± 61 173 ± 13b | 920 ± 73 37.2 ± 5.2c | 85.3 3.5d | 40.0 0.7e |
x100px | para-fluorophenyltropane WIN 35,428 (β-CFT{{efn|Beta (i.e. 2,3 Rectus)-Carbmethoxy-Fluorophenyl-Tropane}}) 11b | F | 14 (15.7 ± 1.4) 22.9 ± 0.4ɑ | 156 (810 ± 59) 100 ± 13b | 85 (835 ± 45) 38.6 ± 9.9c | 51.6 4.4d | 53.2 1.7e |
x100px | para-nitrophenyltropane 11k | NO2 | 10.1 ± 0.10 | ? | ? | ? | ? |
x100px | para-aminophenyltropane RTI-29{{US patent|6479509}} Method of promoting smoking cessation. 11j | NH2 | 9.8 24.8 ± 1.3g | 5110 | 151 | 521.4 | 15.4 |
x100px | para-chlorophenyltropane RTI-31 11c | Cl | 1.12 ± 0.06 3.68 ± 0.09ɑ | 44.5 ± 1.3 5.00 ± 0.05b | 37 ± 2.1 5.86 ± 0.67c | 39.7 1.3d | 33.0 1.7e |
x100px | para-methylphenyltropane RTI-32 Tolpane 11f | Me | 1.71 ± 0.30 7.02 ± 0.30ɑ | 240 ± 27 19.38 ± 0.65b | 60 ± 0.53e 8.42 ± 1.53c | 140 2.8d | 35.1 1.2e |
x100px | para-bromophenyltropane RTI-51 Bromopane 11d | Br | 1.81 (1.69) ± 0.30 | 10.6 ± 0.24 | 37.4 ± 5.2 | 5.8 | 20.7 |
x100px | para-iodophenyltropane RTI-55 (β-CIT) Iometopane 11e | I | 1.26 ± 0.04 1.96 ± 0.09ɑ | 4.21 ± 0.3 1.74 ± 0.23b | 36 ± 2.7 7.51 ± 0.82c | 3.3 0.9d | 28.6 3.8e |
x100px | para-hydroxyphenyltropane 11h | OH | 12.1 ± 0.86 | — | — | — | — |
x100px | para-methoxyphenyltropane 11i | OCH3 | 8.14 ± 1.3 | — | — | — | — |
x100px | para-azidophenyltropane 11l | N3 | 2.12 ± 0.13 | — | — | — | — |
x100px | para-trifluoromethylphenyltropane 11m | CF3 | 13.1 ± 2.2 | — | — | — | — |
x100px | para-acetylaminophenyltropane 11n | NHCOCH3 | 64.2 ± 2.6 | — | — | — | — |
x100px | para-propionylaminophenyltropane 11o | NHCOC2H5 | 121 ± 2.7 | — | — | — | — |
x100px | para-ethoxycarbonylaminophenyltropane 11p | NHCO2C3H5 | 316 ± 48 | — | — | — | — |
x100px | para-trimethylstannylphenyltropane 11q | Sn(CH3)3 | 144 ± 37 | — | — | — | — |
x100px | para-ethylphenyltropane RTI-83 11g | Et | 55 ± 2.1 | 28.4 ± 3.8 (2.58 ± 3.5) | 4030 (3910) ± 381 (2360 ± 230) | 0.5 | 73.3 |
x100px | para-n-propylphenyltropane RTI-282i 11r | n-C3H7 | 68.5 ± 7.1 | 70.4 ± 4.1 | 3920 ± 130 | 1.0 | 57.2 |
x100px | para-isopropylphenyltropane 11s | CH(CH3)2 | 597 ± 52 | 191 ± 9.5 | 75000 ± 5820 | 0.3 | 126 |
x100px | para-vinylphenyltropane RTI-359 11t | CH-CH2 | 1.24 ± 0.2 | 9.5 ± 0.8 | 78 ± 4.1 | 7.7 | 62.9 |
x100px | para-methylethenylphenyltropane RTI-283j 11u | C(=CH2)CH3 | 14.4 ± 0.3 | 3.13 ± 0.16 | 1330 ± 333 | 0.2 | 92.4 |
x100px | para-trans-propenylphenyltropane RTI-296i 11v | trans-CH=CHCH3 | 5.29 ± 0.53 | 11.4 ± 0.28 | 1590 ± 93 | 2.1 | 300 |
x100px | para-allylphenyltropane 11x | CH2CH=CH2 | 32.8 ± 3.1 | 28.4 ± 2.4 | 2480 ± 229 | 0.9 | 75.6 |
x100px | para-ethynylphenyltropane RTI-360 11y | C≡CH | 1.2 ± 0.1 | 4.4 ± 0.4 | 83.2 ± 2.8 | 3.7 | 69.3 |
x100px | para-propynylphenyltropane RTI-281i 11z | C≡CCH3 | 2.37 ± 0.2 | 15.7 ± 1.5 | 820 ± 46 | 6.6 | 346 |
x100px | para-cis-propenylphenyltropane RTI-304 11w | cis-CH=CHCH3 | 15 ± 1.2 | 7.1 ± 0.71 | 2,800k ± 300 | 0.5 | 186.6k |
x140px | para-(Z)-phenylethenylphenyltropane | cis-CH=CHPh | 11.7 ± 1.12 | — | — | — | — |
x100px | para-benzylphenyltropane| | ||||||
CH2-Ph | 526 ± 65 | 7,240 ± 390 (658 ± 35) | 6670 ± 377 (606 ± 277) | 13.7 | 12.6 | ||
x100px | para-phenylethenylphenyltropane | CH2 -C-Ph | 474 ± 133 | 2,710 ± 800 (246 ± 73) | 7,060 ± 1,760 (4,260 ± 1,060) | 5.7 | 14.8 |
x100px | para-phenylethylphenyltropanel| | ||||||
(CH2)2-Ph | 5.14 ± 0.63 | 234 ± 26 (21.3 ± 2.4) | 10.8 ± 0.3 (6.50 ± 0.20) | 45.5 | 2.1 | ||
x100px | para-(E)-phenylethenylphenyltropanel RTI-436 | trans–CH=CHPh | 3.09 ± 0.75 | 335 ± 150 (30.5 ± 13.6) | 1960 ± 383 (1180 ± 231) | 108.4 | 634.3 |
x120px | para-phenylpropylphenyltropanel| | ||||||
(CH2)3-Ph | 351 ± 52 | 1,243 ± 381 (113 ± 35) | 14,200 ± 1,800 (8,500 ± 1,100) | 3.5 | 40.4 | ||
x120px | para-phenylpropenylphenyltropanel| | ||||||
CH=CH-CH2-Ph | 15.8 ± 1.31 | 781 ± 258 (71 ± 24) | 1,250 ± 100 (759 ± 60) | 49.4 | 79.1 | ||
x100px | para-phenylbutylphenyltropanel| | ||||||
(CH2)4-Ph | 228 ± 21 | 4,824 ± 170 (439 ± 16) | 2,310 ± 293 (1,390 ± 177) | 21.1 | 10.1 | ||
x100px | para-phenylethynylphenyltropanel RTI-298{{Cite journal | pmid = 12190324 | year = 2002 | last1 = Blough | first1 = B. E. | last2 = Keverline | last3 = Nie | last4 = Navarro | last5 = Kuhar | last6 = Carroll | title = Synthesis and transporter binding properties of 3β-4′-(phenylalkyl, -phenylalkenyl, and -phenylalkynyl)phenyltropane-2β-carboxylic acid methyl esters: evidence of a remote phenyl binding domain on the dopamine transporter | volume = 45 | issue = 18 | pages = 4029–4037 | journal = Journal of Medicinal Chemistry | doi = 10.1021/jm020098n | first2 = K. I. | first3 = Z. | first4 = H. | first5 = M. J. | first6 = F. I. }} | –≡–Ph | 3.7 ± 0.16 | 46.8 ± 5.8 (4.3 ± 0.53) | 347 ± 25 (209 ± 15) | 12.6 | 93.7 |
x100px | para-phenylpropynylphenyltropanel{{Cite journal|doi=10.1021/jm020098n|pmid=12190324|title=Synthesis and Transporter Binding Properties of 3β-[4'-(Phenylalkyl, -phenylalkenyl, and -phenylalkynl)phenyl]tropane-2β-carboxylic Acid Methyl Esters: Evidence of a Remote Phenyl Binding Domain on the Dopamine Transporter|journal=Journal of Medicinal Chemistry|volume=45|issue=18|pages=4029–37|year=2002|last1=Blough|first1=Bruce E.|last2=Keverline|first2=Kathryn I.|last3=Nie|first3=Zhe|last4=Navarro|first4=Hernán|last5=Kuhar|first5=Michael J.|last6=Carroll|first6=F. Ivy}} | –C≡C-CH2Ph | 1.82 ± 0.42 | 13.1 ± 1.7 (1.19 ± 0.42) | 27.4 ± 2.6 (16.5 ± 1.6) | 7.1 | 15 |
x100px | para-phenylbutynylphenyltropanel RTI-430 | –C≡C(CH2)2Ph | 6.28 ± 1.25 | 2180 ± 345 (198 ± 31) | 1470 ± 109 (885 ± 66) | 347.1 | 234 |
x100px | para-phenylpentynylphenyltropanel | –C≡C-(CH2)3-Ph | 300 ± 37 | 1,340 ± 232 (122 ± 21) | 4,450 ± 637 (2,680 ± 384) | 4.46 | 14.8 |
x100px | para-trimethylsilylethynylphenyltropane | — | — | — | — | — | — |
x100px | para-hydroxypropynylphenyltropane | — | — | — | — | — | — |
x100px | para-hydroxyhexynylphenyltropanel | –C≡C-(CH2)4OH | 57 ± 4 | 828 ± 29 (75 ± 2.6) | 9,500 ± 812 (5,720 ± 489) | 14.5 | 166.6 |
x100px | para-(thiophen-3-yl)phenyltropane Tamagnan | p-thiophene | 12 | 0.017 | 189 | 0.001416 | 15.7 |
x100px | para-biphenyltropane 11aa | Ph | 10.3 ± 2.6f 29.4 ± 3.8ɑ 15.6 ± 0.6 | 95.8 ± 36 (8.7 ± 3.3) | 1,480 ± 269 (892 ± 162) | 6.1 | 94.8 |
x110px | 3β-2-naphthyltropane RTI-318 11bb | 3β-2-naphthyl | 0.51 ± 0.03 3.32 ± 0.08f 3.53 ± 0.09ɑ | 0.80 ± 0.06 (0.07 ± 0.1) | 21.1 ± 1.0 (12.7 ± 0.60) | 1.5 | 41.3 |
x100px | para-bimethoxyphenyltropane 15 | OCH2OCH3h | — | — | — | — | — |
* ɑ[3H]DA uptake displacement Ki value.
|
|
|
=(4′-Monosubstituted 2,3-Thiophene phenyl)-tropanes=
{{sort under}}
class="wikitable sortable sort-under"
|+Tamagnan (thiophene) analogues of para-phenyltropanes. ! Compound structure ! Alphanumeric code ! para-substitution ! N8 ! SERT ! DAT ! NET ! Selectivity ! Selectivity | ||||||||
1 (cocaine) | (—)-Cocaine | CH3 | 1050 | 89 | 3320 | 0.08 | 3.2 | |
2 (β-CIT), (Iometopane) | Iodo | CH3 | 0.46 ± 0.06 | 0.96 ± 0.15 | 2.80 ± 0.40 | 2.1 | 6.1 | |
(R,S-Citalopram) | — | — | 1.60 | 16,540 | 6,190 | 10,338 | 3,869 | |
x100px | 4a | 2-Thiophene | CH3 | 0.15 ± 0.015 | 52 ± 12.8 | 158 ± 12 | 346 | 1,053 |
x100px | 4b (Tamagnan) | 3-Thiophene | CH3 | 0.017 ± 0.004 | 12.1 ± 3 | 189 ± 82 | 710 | 11,118 |
x100px | 4c | 2-(5-Br)-Thiophene | CH3 | 0.38 ± 0.008 | 6.43 ± 0.9 | 324 ± 19 | 17 | 853 |
x100px | 4d | 2-(5-Cl)-Thiophene | CH3 | 0.64 ± 0.04 | 4.42 ± 1.64 | 311 ± 25 | 6.9 | 486 |
x100px | 4e | 2-(5-I)-Thiophene | CH3 | 4.56 ± 0.84 | 22.1 ± 3.2 | 1,137 ± 123 | 4.9 | 249 |
x100px | 4f | 2-(5-NH2)-Thiophene | CH3 | 64.7 ± 3.7 | >10,000 | >30,000 | >155 | >464 |
x100px | 4g | 2-(4,5-NO2)-Thiophene | CH3 | 5,000 | >30,000 | >10,000 | >6.0 | >2.0 |
x100px | 4h | 3-(4-Br)-Thiophene | CH3 | 4.02 ± 0.34 | 183 ± 69 | >10,000 | 46 | >2,488 |
x100px | 5a | 2-Thiophene | H | 0.11 ± 0.006 | 12.2 ± 0.9 | 75.3 ± 9.6 | 111 | 685 |
x100px | 5b | 3-Thiophene | H | 0.23 ± 0.02 | 6.4 ± 0.27 | 39 ± 0.8 | 28 | 170 |
= (3′,4′-Disubstituted phenyl)-tropanes =
File:RTI-318 structure.png
File:RTIthreefivethree.png
File:Phenyltropane 17c.svg
File:RTI-112.svg
class="wikitable"
!Compound | ||||||||
RTI-318 11bb | colspan=2|β-naphthyl | CO2Me | β,β | NMe | 0.5 | 0.81 | 20 | |
Dichloropane (RTI-111ɑ) 17c | Cl | Cl | CO2Me | β,β | NMe | 0.79 | 3.13 | 18.0 |
RTI-88 [recheck] 17e | NH2 | I | CO2Me | β,β | NMe | 1.35 | 1329c | 320c |
RTI-97 17d | NH2 | Br | CO2Me | β,β | NMe | 3.91 | 181 | 282 |
RTI-112b 17b | Cl | Me | CO2Me | β,β | NMe | 0.82 | 10.5 | 36.2 |
RTI-96 17a | F | Me | CO2Me | β,β | NMe | 2.95 | 76 | 520 |
RTI-295 | Et | I | CO2Me | β,β | NMe | 21.3 | 2.96 | 1349 |
RTI-353 (EINT) | Et | I | CO2Me | β,β | NH | 331 | 0.69 | 148 |
RTI-279 | Me | I | CO2Me | β,β | NH | 5.98 | 1.06 | 74.3 |
RTI-280 | Me | I | CO2Me | β,β | NMe | 3.12 | 6.81 | 484 |
Meltzer{{Cite journal | doi = 10.1016/j.bmcl.2003.07.014| pmid = 14592523| title = Synthesis and biological activity of 2-Carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes| journal = Bioorganic & Medicinal Chemistry Letters| volume = 13| issue = 22| pages = 4133–4137| year = 2003| last1 = Meltzer | first1 = P. C. | last2 = McPhee | first2 = M. | last3 = Madras | first3 = B. K. }} | colspan=2|catechol | CO2Me | β,β | NMe | >100 | ? | ? | |
Meltzer | OAc | OAc | CO2Me | β,β | NMe | ? | ? | ? |
- ɑas ·HCl (salt)
- bas ·HCl·2 H2O (salt)
- cSingh gives the reverse value with respect to i.e. 1,329 for NET & 320 for 5-HT
{{sort under}}
class="wikitable sortable sort-under"
|+Para-meta-substituted 2β-carbomethoxy-3α-(4′-substituted phenyl)tropanes ! Compound 150px ! Short Name ! R2 ! R1 ! DA ! 5HT ! NE ! Selectivity ! Selectivity | ||||||||
150px | meta-fluorophenyltropane 16a | F | H | 23 ± 7.8| | ||||
150px | meta-chlorophenyltropane 16b | Cl | H | 10.6 ± 1.8| | ||||
150px | meta-bromophenyltropane 16c | Br | H | 7.93 ± 0.08ɑ| | ||||
|150px | meta-iodophenyltropane 16d | I | H | 26.1 ± 1.7| | ||||
160px | meta-tributylstannylphenyltropane 16e | SnBu3 | H | 1100 ± 170| | ||||
160px | meta-ethynylphenyltropane | C≡CH | H| | |||||
150px | meta-methyl-para-fluorophenyltropane RTI-96 17a | CH3 | F | 2.95 ± 0.58| | ||||
150px | meta-methyl-para-chlorophenyltropane RTI-112c 17b | CH3 | Cl | 0.81 ± 0.05 | 10.5 ± 0.05 | 36.2 ± 1.0 | 13.0 | 44.7 |
150px | meta-para-dichlorophenyltropane RTI-111b{{cite journal|doi=10.1021/jm00059a010|pmid=8464040|title=Substituted 3-phenyltropane analogs of cocaine: Synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging|journal=Journal of Medicinal Chemistry|volume=36|issue=7|pages=855–62|year=1993|last1=Meltzer|first1=P. C.|last2=Liang|first2=A. Y.|last3=Brownell|first3=A. L.|last4=Elmaleh|first4=D. R.|last5=Madras|first5=B. K.}} Dichloropane 17c | Cl | Cl | 0.79 ± 0.08b | 3.13 ± 0.36b | 18.0 ± 0.8 17.96 ± 0.85bd | 4.0b | 22.8b |
160px | meta-bromo-para-aminophenyltropane RTI-97 17d | Br | NH2 | 3.91 ± 0.59 | 181 | 282 | 46.2 | 72.1 |
160px | meta-iodo-para-aminophenyltropane RTI-88 17e | I | NH2 | 1.35 ± 0.11 | 120 ± 4 | 1329 ± 124 | 88.9 | 984 |
160px | meta-iodo-para-azidophenyltropane 17f | I | N3 | 4.93 ± 0.32| | ||||
- ɑIC50 determined in Cynomolgous monkey caudate-putamen
- bas ·HCl (salt)
- cas ·HCl·2 H2O (salt)
- dNEN
{{sort under}}
class="wikitable sortable sort-under"
|+3β-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropanes{{cite journal|last1=Jin|first1=Chunyang|last2=Navarro|first2=Hernán A.|last3=Ivy Carroll|first3=F.|title=Synthesis and structure–activity relationship of 3β-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3β-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters|journal=Bioorganic & Medicinal Chemistry|volume=17|issue=14|year=2009|pages=5126–5132|issn=0968-0896|doi=10.1016/j.bmc.2009.05.052|pmid=19523837|pmc=2747657}} ! Structure 150px ! Compound ! R ! X ! n ! Inhibition of [3H]WIN 35,428 ! Inhibition of [3H]Paroxetine ! Inhibition of [3H]Nisoxetine ! NET/DAT ! NET/5-HTT | |||||||||
Cocaine | Des-thio/sulfinyl/sulfonyl H | H | Desmethyl 0 | 89.1 | 95 | 1990 | 22 | 21 | |
para-methoxyphenyltropane Singh: 11i | Des-thio/sulfinyl/sulfonyl OCH3 | H | 0 | 6.5 ± 1.3 | 4.3 ± 0.5 | 1110 ± 64 | 171 | 258 | |
190px | 7a | CH3 | H | 0 | 9 ± 3 | 0.7 ± 0.2 | 220 ± 10 | 24 | 314 |
200px | 7b | C2H5 | H | 0 | 232 ± 34 | 4.5 ± 0.5 | 1170 ± 300 | 5 | 260 |
200px | 7c | CH(CH3)2 | H | 0 | 16 ± 2 | 23 ± 2 | 129 ± 2 | 8 | 7 |
200px | 7d | CF3 | H | 0 | 200 ± 70 | 8 ± 2 | 1900 ± 300 | 10 | 238 |
180px | 7e | CH3 | Br | 0 | 10.1 ± 1 | 0.6 ± 0.2 | 121 ± 12 | 12 | 202 |
180px | 7f | CH3 | Br | 1 | 76 ± 18 | 3.2 ± 0.4 | 690 ± 80 | 9 | 216 |
180px | 7g | CH3 | H | 1 | 91 ± 16 | 4.3 ± 0.6 | 515 ± 60 | 6 | 120 |
180px | 7h | CH3 | H | 2 | >10,000 | 208 ± 45 | >10,000 | 1 | 48 |
= (2′,4′-Disubstituted phenyl)-tropanes =
{{sort under}}
class="wikitable sortable sort-under"
|+Ortho-para-substituted (2′,4′-disubstituted phenyltropanes) ! Compound structure ! Trivial IUPAC ! R2 ! R1 ! DA ! 5HT ! NE ! Selectivity ! Selectivity | |||
185px | ortho,para-dinitrophenyltropane{{cite journal|author=R. H. Kline, Davies, E. Saikali, T. Sexton & S.R. Childers|title=Novel 2-substituted cocaine analogs: Binding properties at dopamine transport sites in rat striatum|journal=European Journal of Pharmacology|volume= 244|issue=1|pages= 93–97|year=1993|pmid=8420793|doi=10.1016/0922-4106(93)90063-f}} | NO2 | NO2 | |
= (3′,4′,5′-Trisubstituted ''para''-methoxyphenyl)-tropanes =
{{sort under}}
class="wikitable sortable sort-under"
|+Para-meta(3′)-meta(5′)-(di-meta)-substituted 2β-carbomethoxy-(3′,4′,5′-substituted phenyl)tropanes{{Cite journal|pmc=2841478|id=Table 1|year=2008|last1=Jin|first1=C|title=Development of 3-Phenyltropane Analogs with High Affinity for the Dopamine and Serotonin Transporters and Low Affinity for the Norepinephrine Transporter|journal=Journal of Medicinal Chemistry|volume=51|issue=24|pages=8048–8056|last2=Navarro|first2=H. A.|last3=Carroll|first3=F. I.|doi=10.1021/jm801162z|pmid=19053748}} ! Structure ! {{verth|va=middle|Short Name ! {{verth|va=middle|R2 ! {{verth|va=middle|R3 ! {{verth|va=middle|OR1 ! DAT ! 5-HTT ! NET ! Selectivity ! Selectivity | |||||||||
Cocaine| | |||||||||
|89.1 | 95 | 1990 | 22 | 21 | |||||
6 RTI-112| | |||||||||
|0.82 ± 0.05 | 0.95 ± 0.04 | 21.8 ± 0.6 | 27 | 23 | |||||
File:Cocaine analog Carroll 7a.svg | 7a 11i | H | H | CH3 | 6.5 ± 1.3 | 4.3 ± 0.5 | 1110 ± 64 | 171 | 258 |
File:Cocaine analog Carroll 7b.svg | 7b | H | H | C2H5 | 92 ± 8 | 1.7 ± 0.4 | 1690 ± 50 | 18 | 994 |
File:Cocaine analog Carroll 7c.svg | 7c | F | H | CH3 | 16 ± 1 | 4.8 ± 0.5 | 270 ± 50 | 17 | 56 |
File:Cocaine analog Carroll 7d.svg | 7d | Br | H | CH3 | 47 ± 15 | 3.1 ± 0.1 | 160 ± 20 | 3 | 52 |
File:Cocaine analog Carroll 7f.svg | 7f | Br | Br | CH3 | 92 ± 22 | 2.9 ± 0.1 | 4100 ± 400ɑ | 45 | 1413 |
File:Cocaine analog Carroll 7e.svg | 7e | I | H | CH3 | 170 ± 60 | 3.5 ± 0.4 | 180 ± 20 | 1 | 51 |
File:Cocaine analog Carroll 7g.svg | 7g | I | I | CH3 | 1300 ± 200 | 7.5 ± 0.8 | 180 ± 20 | 4 | 667 |
ɑN=2
= (2′,4′,5′-Trisubstituted phenyl)-tropanes =
{{sort under}}
class="wikitable sortable sort-under"
|+Ortho-para(4′)-meta(5′)-trisubstituted 2β-carbomethoxy-(2′,4′,5′-substituted phenyl)tropanes ! Structure ! Short Name ! {{verth|va=middle|R1 ! {{verth|va=middle|R2 ! {{verth|va=middle|R3 ! {{verth|va=middle|DAT}} ! {{verth|va=middle|5-HTT}} ! {{verth|va=middle|NET}} ! Selectivity ! Selectivity | |||||||||
x130px | para-ethyl-ortho, meta-diiodophenyltropane | iodo | ethyl | iodo | {{sdash}} | {{sdash}} | {{sdash}} | {{sdash}} | {{sdash}} |
2-Carbmethoxy modified (replaced/substituted)
= General 2-carbmethoxy modifications =
== 2β-substitutions of ''p''-methoxy-phenyltropanes ==
{{sort-under}}
class="wikitable sortable sort-under"
|+Para-OCH3-(3β-(4-Methoxyphenyl)tropane-2β-carboxylic acid ester analogues{{cite journal|pmc=2841478|id=Table 2|year=2008|last1=Jin|first1=C|title=Development of 3-Phenyltropane Analogs with High Affinity for the Dopamine and Serotonin Transporters and Low Affinity for the Norepinephrine Transporter|journal=Journal of Medicinal Chemistry|volume=51|issue=24|pages=8048–8056|last2=Navarro|first2=H. A.|last3=Carroll|first3=F. I.|doi=10.1021/jm801162z|pmid=19053748}} ! Structure ! {{verth|Short Name ! CO2R (2β-substituted) ! DAT ! 5-HTT ! NET ! Selectivity ! Selectivity | |||||||
File:Cocaine analog Carroll 7a.svg | 7a 11i | CH3 | 6.5 ± 1.3 | 4.3 ± 0.5 | 1110 ± 64 | 171 | 258 |
File:Cocaine analog Carrol 8a.svg | 8a | (CH3)2CH | 14 ± 3 | 135 ± 35 | 2010 ± 200 | 144 | 15 |
File:Cocaine analog Carrol 8b.svg | 8b | cyclopropane | 6.0 ± 2 | 29 ± 3 | 1230 ± 140 | 205 | 42 |
File:Cocaine analog Carrol 8c.svg | 8c | cyclobutane | 13 ± 3 | 100 ± 8 | >3000 | 231 | 30 |
File:Cocaine analog Carrol 8d.svg | 8d | O2N...1,4-xylene...(CH2)2 | 42 ± 8 | 2.9 ± 0.2 | 330 ± 20 | 8 | 114 |
File:Cocaine analog Carrol 8e.svg | 8e | H2N...1,4-xylene...(CH2)2 | 7.0 ± 2 | 8.3 ± 0.4 | 2200 ± 300ɑ | 314 | 265 |
File:Cocaine analog Carrol 8f.svg | 8f | CH3CONH...1,4-xylene...(CH2)2 | 6.0 ± 1 | 5.5 ± 0.5 | 1460 ± 30 | 243 | 265 |
File:Cocaine analog Carrol 8g.svg | 8g | H2N...2-bromo-1,4-dimethylbenzene...(CH2)2 | 3.3 ± 1.4 | 4.1 ± 0.6 | 1850 ± 90 | 561 | 451 |
File:Cocaine analog Carrol 8h.svg | 8h | H2N...1,3-dibromo-2,5-dimethylbenzene...(CH2)2 | 15 ± 6 | 2.0 ± 0.4 | 2710 ± 250ɑ | 181 | 1360 |
File:Cocaine analog Carrol 8i.svg | 8i | H2N...2-iodo-1,4-dimethylbenzene...(CH2)2 | 2.5 ± 0.7 | 3.5 ± 1 | 2040 ± 300ɑ | 816 | 583 |
File:Cocaine analog Carrol 8j.svg | 8j | H2N...1,3-diiodo-2,5-dimethylbenzene...(CH2)2 | 102 ± 15 | 1.0 ± 0.1 | 2600 ± 200ɑ | 25 | 2600 |
File:Cocaine analog Carroll 9.svg | 9 | 3-(4-methylphenyl)-1,2-oxazole | 18 ± 6 | 860 ± 170 | >3000 | 167 | 3 |
ɑN=2
== 2β-carboxy side-chained (''p''-chloro/iodo/methyl) phenyltropanes ==
class="wikitable sortable"
|+Multi-substituted structures of 2β-ester-3β-phenyltropanes ! Compound ! Short Name ! R ! X ! IC50 (nM) ! IC50 (nM) ! IC50 (nM) ! Selectivity ! Selectivity | ||||||||
x100px | 23a | CH(CH3)2 | H | 85.1 ± 2.5 | 23121 ± 3976 | 32047 ± 1491 | 272 | 376 |
x120px | 23b | C6H5 | H | 76.7 ± 3.6 | 106149 ± 7256 | 19262 ± 593 | 1384 | 251 |
x100px | 24a | CH(CH3)2 | Cl | 1.4 ± 0.13 6.04 ± 0.31ɑ | 1400 ± 7 128 ± 15b | 778 ± 21 250 ± 0.9c | 1000 21.2d | 556 41.4e |
x100px | 24b | cyclopropyl | Cl | 0.96 ± 0.10 | 168 ± 1.8 | 235 ± 8.39 | 175 | 245 |
x120px | 24c | C6H5 | Cl | 1.99 ± 0.05 5.25 ± 0.76ɑ | 2340 ± 27 390 ± 34b | 2960 ± 220 242 ± 30c | 1176 74.3d | 1.3 41.6e |
x150px | 24d | C6H4-4-I | Cl | 32.6 ± 3.9 | 1227 ± 176 | 967.6 ± 26.3 | 37.6 | 29.7 |
x120px | 24e | C6H4-3-CH3 | Cl | 9.37 ± 0.52 | 2153 ± 143 | 2744 ± 140 | 230 | 293 |
x140px | 24f | C6H4-4-CH3 | Cl | 27.4 ± 1.5 | 1203 ± 42 | 1277 ± 118 | 43.9 | 46.6 |
x120px | 24g | C6H4-2-CH3 | Cl | 3.91 ± 0.23 | 3772 ± 384 | 4783 ± 387 | 965 | 1223 |
x140px | 24h | C6H4-4-Cl | Cl | 55 ± 2.3 | 16914 ± 1056 | 4883 ± 288 | 307 | 88.8 |
x150px | 24i | C6H4-4-OCH3 | Cl | 71 ± 5.6 | 19689 ± 1843 | 1522 ± 94 | 277 | 21.4 |
x150px | 24j | (CH2)2C6H4-4-NO2 | Cl | 2.71 ± 0.13 | - | - | - | - |
x150px | 24k | (CH)2C6H4-4-NH2 | Cl | 2.16 ± 0.25 | - | - | - | - |
x150px | 24l | (CH2)2C6H3-3-I-4-NH2 | Cl | 2.51 ± 0.25 | - | - | - | - |
x150px | 24m | (CH2)2C6H3-3-I-4-N3 | Cl | 14.5 ± 0.94 | - | - | - | - |
x150px | 24n | (CH2)2C6H4-4-N3 | Cl | 6.17 ± 0.57 | - | - | - | - |
x150px | 24o | (CH2)2C6H4-4-NCS | Cl | 5.3 ± 0.6 | - | - | - | - |
x170px | 24p | (CH2)2C6H4-4-NHCOCH2Br | Cl | 1.73 ± 0.06 | - | - | - | - |
x100px | 25a | CH(CH3)2 | I | 0.43 ± 0.05 2.79 ± 0.13ɑ | 66.8 ± 6.53 12.5 ± 1.0b | 285 ± 7.6 41.2 ± 3.0c | 155 4.5d | 663 14.8e |
x100px | 25b | cyclopropyl | I | 0.61 ± 0.08 | 15.5 ± 0.72 | 102 ± 11 | 25.4 | 167 |
x120px | 25c | C6H5 | I | 1.51 ± 0.34 6.85 ± 0.93ɑ | 184 ± 22 51.6 ± 6.2b | 3791 ± 149 32.7 ± 4.4c | 122 7.5d | 2510 4.8e |
x100px | | 26a | CH(CH3)2 | CH3 | 6.45 ± 0.85 15.3 ± 2.08ɑ | 6090 ± 488 917 ± 54b | 1926 ± 38 73.4 ± 11.6c | 944 59.9d | 299 4.8e |
x120px | 26b | CH(C2H5)2 | CH3 | 19.1 ± 1 | 4499 ± 557 | 3444 ± 44 | 235 | 180 |
x100px | 26c | cyclopropyl | CH3 | 17.8 ± 0.76 | 485 ± 21 | 2628 ± 252 | 27.2 | 148 |
x110px | 26d | cyclobutyl | CH3 | 3.74 ± 0.52 | 2019 ± 133 | 4738 ± 322 | 540 | 1267 |
x120px | 26e | cyclopentyl | CH3 | 1.68 ± 0.14 | 1066 ± 109 | 644 ± 28 | 634 | 383 |
x120px | 26f | C6H5 | CH3 | 3.27 ± 0.06 9.13 ± 0.79ɑ | 24500 ± 1526 1537 ± 101b | 5830 ± 370 277 ± 23c | 7492 168d | 1783 30.3e |
x120px | 26g | C6H4-3-CH3 | CH3 | 8.19 ± 0.90 | 5237 ± 453 | 2136 ± 208 | 639 | 261 |
x140px | 26h | C6H4-4-CH3 | CH3 | 81.2 ± 16 | 15954 ± 614 | 4096 ± 121 | 196 | 50.4 |
x120px | 26i | C6H4-2-CH3 | CH3 | 23.2 ± 0.97 | 11040 ± 504 | 25695 ± 1394 | 476 | 1107 |
x150px | 26j | C6H4-4-Cl | CH3 | 117 ± 7.9 | 42761 ± 2399 | 9519 ± 864 | 365 | 81.3 |
x150px | 26k | C6H4-4-OCH3 | CH3 | 95.6 ± 8.8 | 82316 ± 7852 | 3151 ± 282 | 861 | 33.0 |
- ɑKi value for displacement of [3H]DA uptake.
- bKi value for displacement of [3H]5-HT uptake.
- cKi value for displacement of [3H]NE uptake.
- d[3H]5-HT uptake to [3H]DA uptake ratio.
- e[3H]NE uptake to [3H]DA uptake ratio.
= Carboxyaryl =
class="wikitable"
!Compound!!X!!2 Position!!config!!8!! DA !! 5-HT !! NE | |||||||
RTI-122 | I | | ||||||
CO2Ph | β,β | NMe | 1.50 | 184 | 3,791 | ||
RTI-113 | Cl | | ||||||
CO2Ph | β,β | NMe | 1.98 | 2,336 | 2,955 | ||
RTI-277 | NO2 | | ||||||
CO2Ph | β,β | NMe | 5.94 | 2,910 | 5,695 | ||
RTI-120 [recheck] | Me | | ||||||
CO2Ph | β,β | NMe | 3.26 | 24,471 | 5,833 | ||
RTI-116 | Cl | | ||||||
CO2(p-C6H4I) | β,β | NMe | 33 | 1,227 | 968 | ||
RTI-203 | Cl | CO2(m-C6H4Me) | β,β | NMe | 9.37 | 2153 | 2744 |
RTI-204 | Cl | | ||||||
CO2(o-C6H4Me) | β,β | NMe | 3.91 | 3,772 | 4,783 | ||
RTI-205 | Me | | ||||||
CO2(m-C6H4Me) | β,β | NMe | 8.19 | 5,237 | 2,137 | ||
RTI-206 | Cl| | ||||||
CO2(p-C6H4Me) | β,β | NMe | 27.4 | 1,203 | 1,278 |
== 2-Phenyl-3-Phenyltropanes ==
{{sort under}}
class="wikitable sortable sort-under"
|+2-Phenyl-3-phenyltropane binding affinities and inhibition of DA & 5-HT Uptake ! Compound Structure ! {{verth|Short Name ! {{verth|Stereochemistry}} ! X ! DAT ! DAT ! 5-HTT ! [3H]DA uptake Ki (nM) ! [3H]5-HT uptake Ki (nM) ! Selectivity | |||||||||
Cocaine | (2β,3β) | (H) | 89 ± 4.8 | 281 | 1050 ± 89 | 423 | 155 | 0.4 | |
x105px | 67a | 2β,3β | H | 12.6 ± 1.8 | 14.9 | 21000 ± 3320 | 28.9 | 1100 | 38.1 |
x155px | 67b | 2β,3α | H | - | 13.8| | ||||
|11.7 | 753 | 64.3 | |||||||
x135px | 67c | 2α,3α | H | 690 ± 37| | |||||
|41300 ± 5300| | |||||||||
x170px | 68 | 2β,3α | F | | ||||||
|6.00| | |||||||||
|4.58 | 122 | 26.6 | |||||||
x100px | 69a | 2β,3β | CH3 | 1.96 ± 0.08 | 2.58 | 11000 ± 83 | 2.87 | 73.8 | 25.7 |
x170px | 69b | 2β,3α | CH3 | | ||||||
|2.87| | |||||||||
|4.16 | 287 | 69.0 | |||||||
x145px | 69c | 2α,3α | CH3 | 429 ± 59| | |||||
|15800 ± 3740| | |||||||||
= Carboxyalkyl =
File:RTI-77 structure.png
File:RTI-121.png
File:RTI-150.png
class="wikitable"
!Code!!X!!2 Position!!config!!8!! DA !! 5-HT !! NE | |||||||
RTI-77 | Cl | CH2C2(3-iodo-p-anilino) | β,β | NMe | 2.51 | — | 2247 |
RTI-121 IPCIT | I | | ||||||
CO2Pri | β,β | NMe | 0.43 | 66.8 | 285 | ||
RTI-153 | I | | ||||||
CO2Pri | β,β | NH | 1.06 | 3.59 | 132 | ||
RTI-191 | I | | ||||||
CO2Prcyc | β,β | NMe | 0.61 | 15.5 | 102 | ||
RTI-114 | Cl | | ||||||
CO2Pri | β,β | NMe | 1.40 | 1,404 | 778 | ||
RTI-278 | NO2 | | ||||||
CO2Pri | β,β | NMe | 8.14 | 2,147 | 4,095 | ||
RTI-190 | Cl | | ||||||
CO2Prcyc | β,β | NMe | 0.96 | 168 | 235 | ||
RTI-193 | Me | | ||||||
CO2Prcyc | β,β | NMe | 1.68 | 1,066 | 644 | ||
RTI-117 | Me | | ||||||
CO2Pri | β,β | NMe | 6.45 | 6,090 | 1,926 | ||
RTI-150 | Me | | ||||||
CO2Bucyc | β,β | NMe | 3.74 | 2,020 | 4,738 | ||
RTI-127 | Me | | ||||||
CO2C(H)Et2 | β,β | NMe | 19 | 4500 | 3444 | ||
RTI-338 | ethyl| | ||||||
CO2C2Ph | β,β | NMe | 1104 | 7.41 | 3366 |
Use of a cyclopropyl ester appears to enable better MAT retention than does the choice of isopropyl ester.
Use of a cycBu resulted in greater DAT selectivity than did the cycPr homologue.
== 2-Alkyl Esters & Ethers ==
=== Esters (2-Alkyl) ===
class="wikitable sortable"
|+2β-Alkyl Ester Phenyltropanes ! Structure ! Short Name ! 2β=R ! Ki (nM) ! IC50 (nM) ! Selectivity | |||||
x110px | 59a | CH=CHCO2CH3 | 22 ± 2 | 123 ± 65 | 5.6 |
x110px | 59b | CH2CH2CO2CH3 | 23 ± 2 | 166 ± 68 | 7.2 |
x120px | 59c | (CH2)2CH=CHCO2CH3 | 20 ± 2 | 203 ± 77 | 10.1 |
x120px | 59d | (CH22)4CO2CH3 | 30 ± 2 | 130 ± 7 | 4.3 |
x90px | 59e | CH=CHCH2OH | 26 ± 3 | 159 ± 43 | 6.1 |
x90px | 59f | CH2CH2CH2OH | 11 ± 1 | 64 ± 32 | 5.8 |
x110px | 59g | CH2CH2COC6H5 | 28 ± 2 | 47 ± 15 | 1.7 |
=== Ethers (2-Alkyl) ===
{{See also|{{PAGENAME}}#Paroxetine homologues|l1=N-desmethyl Paroxetine homologues|selfref=y}}
{{sort under}}
class="wikitable sortable sort-under"
|+2-Alkyl Ether Phenyltropanes ! Molecular Structure ! Short Name ! {{verth|Stereochemistry}} ! DAT ! 5-HTT ! NET ! Selectivity ! Selectivity | |||||||
Paroxetine | 623 ± 25 | 0.28 ± 0.02 | 535 ± 15 | 0.0004 | 0.8 | ||
x130px | R-60a | 2β,3β | 308 ± 20 | 294 ± 18 | 5300 ± 450 | 0.9 | 17.2 |
x115px | R-60b | 2α,3β | 172 ± 8.8 | 52.9 ± 3.6 | 26600 ± 1200 | 0.3 | 155 |
x195px | R-60c | 2β,3α | 3.01 ± 0.2 | 42.2 ± 16 | 123 ± 9.5 | 14.1 | 40.9 |
x130px | S-60d | 2β,3β | 1050 ± 45 | 88.1 ± 2.8 | 27600 ± 1100 | 0.08 | 26.3 |
x115px | S-60e | 2α,3β | 1500 ± 74 | 447 ± 47 | 2916 ± 1950 | 0.3 | 1.9 |
x195px | S-60f | 2β,3α | 298 ± 17 | 178 ± 13 | 12400 ± 720 | 0.6 | 41.6 |
= Carboxamides =
{{US Patent|5736123}}
File:RTI-183 structure.png
File:RTI-229 structure.png
File:RTI-227 structure.png
{{sort-under}}
class="wikitable sortable sort-under"
!Structure | ||||||||||
x100px | RTI-106 27b | Cl | CON(H)Me | β,β | NMe | 12.4 ± 1.17 | 1584 ± 62 | 1313 ± 46 | 106 | 128 |
x100px | RTI-118 27a | Cl | CONH2 | β,β | NMe | 11.5 ± 1.6 | 4270 ± 359 | 1621 ± 110 | 141 | 371 |
x100px | RTI-222 29d | Me | morpholinyl | β,β | NMe | 11.7 ± 0.87 | 23601 ± 1156 | >100K | >8547 | 2017 |
x100px | RTI-129 27e | Cl | CONMe2 | β,β | NMe | 1.38 ± 0.1 | 942 ± 48 | 1079 ± 102 | 792 | 683 |
x100px | RTI-146 27d | Cl | CONHCH2OH | β,β | NMe | 2.05 ± 0.23 | 144 ± 3 | 97.8 ± 10 | 47.7 | 70.2 |
x100px | RTI-147 27i | Cl | CON(CH2)4 | β,β | NMe | 1.38 ± 0.03 | 3,950 ± 72 | 12400 ± 1207 | 8985 | 2862 |
x100px | RTI-156 | Cl | CON(CH2)5 | β,β | NMe | 6.61 | 5832 | 3468 | ||
x100px | RTI-170 | Cl | CON(H)CH2C≡CH | β,β | NMe | 16.5 | 1839 | 4827 | ||
x100px | RTI-172 | Cl | CON(H)NH2 | β,β | NMe | 44.1 | 3914 | 3815 | ||
x130px | RTI-174 | Cl | CONHCOMe | β,β | NMe | 158 | >43K | >125K | ||
x160px | RTI-182 | Cl | CONHCH2COPh | β,β | NMe | 7.79 | 1722 | 827 | ||
x110px | RTI-183✲ 27 g | Cl | CON(OMe)Me | β,β | NMe | 0.85 ± 0.06 | 549 ± 18.5 | 724 ± 94 | 852 | 646 |
x110px | RTI-186 29c | Me | CON(OMe)Me | β,β | NMe | 2.55 ± 0.43 | 422 ± 26 | 3402 ± 353 | 1334 | 165 |
x100px | RTI-198 27h | Cl | CON(CH2)3 | β,β | NMe | 6.57 ± 0.67 | 990 ± 4.8 | 814 ± 57 | 124 | 151 |
x100px | RTI-196 27c | Cl | CONHOMe | β,β | NMe | 10.7 ± 1.25 | 9907 ± 632 | 43700 ± 1960 | 4084 | 926 |
x160px | RTI-201 | Cl | CONHNHCOPh | β,β | NMe | 91.8 | >20K | >48K | ||
x110px | RTI-208 27j | Cl | CONO(CH2)3 | β,β | NMe | 1.47 ± 0.13 | 1083 ± 76 | 2470 ± 56 | 1680 | 737 |
x110px | RTI-214 27l | Cl | CON(-CH2CH2-)2O | β,β | NMe | 2.90 ± 0.3 | 8545 ± 206 | 88769 ± 1855 | 30610 | 2946 |
x110px | RTI-215 27f | Cl | CONEt2 | β,β | NMe | 5.48 ± 0.19 | 5532 ± 299 | 9433 ± 770 | 1721 | 1009 |
x150px | RTI-217 | Cl | CONH(m-C6H4OH) | β,β | NMe | 4.78 | >30K | >16K | ||
x100px | RTI-218✲ | Cl | CON(Me)OMe | β,β | NMe | 1.19 | 520 | 1911 | ||
x150px | RTI-226 27 m | Cl | CONMePh | β,β | NMe | 45.5 ± 3 | 2202 ± 495 | 23610 ± 2128 | 519 | 48.4 |
x100px | RTI-227 | I | CONO(CH2)3 | β,β | NMe | 0.75 | 446 | 230 | ||
x100px | RTI-229{{cite journal|doi=10.1002/(SICI)1099-1344(199903)42:3<281::AID-JLCR188>3.0.CO;2-X|title=Synthesis of 3β-(4-[125I]iodophenyl)tropane-2-β-pyrrolidine carboxamide ([125I]RTI-229)|journal=Journal of Labelled Compounds and Radiopharmaceuticals|volume=42|issue=3|pages=281–286|year=1999|last1=Zhong|first1=Desong|last2=Kotian|first2=Pravin|last3=Wyrick|first3=Christopher D.|last4=Seltzman|first4=Herbert H.|last5=Kepler|first5=John A.|last6=Kuhar|first6=Michael J.|last7=Boja|first7=John W.|last8=Carroll|first8=F. Ivy}} 28a | I | CON(CH2)4 | β,β | NMe | 0.37 ± 0.04 | 991 ± 21 | 1728 ± 39 | 4670 | 2678 |
x100px | 27k | 6.95 ± 1.21 | 1752 ± 202 | 3470 ± 226 | 499 | 252 | ||||
x100px | 28b | 1.08 ± 0.15 | 103 ± 6.2 | 73.9 ± 8.1 | 68.4 | 95.4 | ||||
x110px | 28c | 0.75 ± 0.02 | 357 ± 42 | 130 ± 15.8 | 173 | 476 | ||||
x100px | 29a | 41.8 ± 2.45 | 4398 ± 271 | 6371 ± 374 | 152 | 105 | ||||
x110px | 29b | 24.7 ± 1.93 | 6222 ± 729 | 33928 ± 2192 | 1374 | 252 |
✲RTI-183 and RTI-218 suggest possible copy-error, seeing as "CON(OMe)Me" & "CON(Me)OMe" difference between methyl & methoxy render as the same.
class="wikitable sortable sort-under"
|+2β-Carboxamide-3β-Phenyltropanes ! Compound ! Short Name ! R ! X ! IC50 (nM) ! IC50 (nM) ! IC50 (nM) ! Selectivity ! Selectivity | |||||||
rowspan=5|x100px | |||||||
29a | NH2 | CH3 | 41.8 ± 2.45 | 6371 ± 374 | 4398 ± 271 | 152 | 105 |
29b | N(CH2CH3)2 | CH3 | 24.7 ± 1.93 | 33928 ± 2192 | 6222 ± 729 | 1374 | 252 |
29c RTI-186 | N(OCH3)CH3 | CH3 | 2.55 ± 0.43 | 3402 ± 353 | 422 ± 26 | 1334 | 165 |
29d RTI-222 | 4-morpholine | CH3 | 11.7 ± 0.87 | >100000 | 23601 ± 1156 | >8547 | 2017 |
==Carboxamide linked phenyltropanes dimers==
File:Phenyltropane para chloro dimer.svg
File:Phenyltropane para methyl dimer.svg
File:PhenyltropaneDimerC2Benzenelink.svg
File:PhenyltropaneDimerC2amide.svg
File:PhenyltropaneDimer.svg
Dimers of phenyltropanes, connected in their dual form using the C2 locant as altered toward a carboxamide structural configuring (in contrast and away from the usual inherent ecgonine carbmethoxy), as per Frank Ivy Carroll's patent inclusive of such chemical compounds, possibly so patented due to being actively delayed pro-drugs in vivo.
= Heterocycles =
These heterocycles are sometimes referred to as the "bioisosteric equivalent" of the simpler esters from which they are derived. A potential disadvantage of leaving the ββ-ester unreacted is that in addition to being hydrolyzable, it can also epimerize{{Cite journal
| pmid = 8411004
| year = 1993
| last1 = Carroll | first1 = F. I.
| last2 = Gray
| last3 = Abraham
| last4 = Kuzemko
| last5 = Lewin
| last6 = Boja
| last7 = Kuhar
| title = 3-Aryl-2-(3′-substituted-1′,2′,4'-oxadiazol-5′-yl)tropane analogues of cocaine: affinities at the cocaine binding site at the dopamine, serotonin, and norepinephrine transporters
| volume = 36
| issue = 20
| pages = 2886–2890
| journal = Journal of Medicinal Chemistry
| doi = 10.1021/jm00072a007
}} to the energetically more favorable trans configuration. This can happen to cocaine also.
File:HeterocyclicMEPCmpndModel34.png
Several of the oxadiazoles contain the same number and types of heteroatoms, while their respective binding potencies display 8×-15× difference. A finding that would not be accounted for by their affinity originating from hydrogen bonding.
To explore the possibility of electrostatic interactions, the use of molecular electrostatic potentials (MEP) were employed with model compound 34 (replacing the phenyltropane moiety with a methyl group). Focusing on the vicinity of the atoms @ positions A—C, the minima of electrostatic potential near atom position A (ΔVmin(A)), calculated with semi-empirical (AM1) quantum mechanics computations (superimposing the heterocyclic and phenyl rings to ascertain the least in the way of steric and conformational discrepancies) found a correlation between affinity @ DAT and ΔVmin(A): wherein the values for the latter for 32c = 0, 32g = -4, 32h = -50 & 32i = -63 kcal/mol.
In contrast to this trend, it is understood that an increasingly negative ΔVmin is correlated with an increase of strength in hydrogen bonding, which is the opposing trend for the above; this indicates that the 2β-substituents (at least for the heterocyclic class) are dominated by electrostatic factors for binding in-the-stead of the presumptive hydrogen bonding model for this substituent of the cocaine-like binding ligand.{{efn| ←[https://www.erowid.org/archive/rhodium/pdf/cocaineanalogs.pdf#16 Page #940 (16th page of article)] underneath Table 8., above § 4}}
== 3-Substituted-isoxazol-5-yl ==
class="wikitable sortable"
|+N-methylphenyltropanes with 1R β,β stereochemistry. ! Code ! X ! R ! DA ! NE ! 5HT | |||||
RTI-165 | Cl | 3-methylisoxazol-5-yl | 0.59 | 181 | 572 |
RTI-171 | Me | 3-methylisoxazol-5-yl | 0.93 | 254 | 3818 |
RTI-180 | I | 3-methylisoxazol-5-yl | 0.73 | 67.9 | 36.4 |
RTI-177 β-CPPIT 32g | Cl | 3-phenylisoxazol-5-yl | 1.28 ± 0.18 | 504 ± 29 | 2420 ± 136 |
RTI-176 | Me | 3-phenylisoxazol-5-yl | 1.58 | 398 | 5110 |
RTI-181 | I | 3-phenylisoxazol-5-yl | 2.57 | 868 | 100 |
RTI-184 | H | methyl | 43.3 | — | 6208 |
RTI-185 | H | Ph | 285 | — | >12K |
RTI-334 | Cl | 3-ethylisoxazol-5-yl | 0.50 | 120 | 3086 |
RTI-335 | Cl | isopropyl | 1.19 | 954 | 2318 |
RTI-336 | Cl | 3-(4-methylphenyl)isoxazol-5-yl | 4.09 | 1714 | 5741 |
RTI-337 | Cl | 3-t-butyl-isoxazol-5-yl | 7.31 | 6321 | 37K |
RTI-345 | Cl | p-chlorophenyl | 6.42 | 5290 | >76K |
RTI-346 | Cl | p-anisyl | 1.57 | 762 | 5880 |
RTI-347 | Cl | p-fluorophenyl | 1.86 | 918 | 7257 |
RTI-354 | Me | 3-ethylisoxazol-5-yl | 1.62 | 299 | 6400 |
RTI-366 | Me | R = isopropyl | 4.5 | 2523 (1550) | 42,900 (3900) |
RTI-371 | Me | p-chlorophenyl | 8.74 | >100K (60,200) | >100K (9090) |
RTI-386 | Me | p-anisyl | 3.93 | 756 (450) | 4027 (380) |
RTI-387 | Me | p-fluorophenyl | 6.45 | 917 (546) | >100K (9400) |
== 3-Substituted-1,2,4-oxadiazole ==
File:RTI-130 structure.png
File:RTI-126.png
{{sort under}}
class="wikitable sortable sort-under"
|+Heterocyclic (N-methyl)phenyltropanes with 1R stereochemistry. ! Structure ! Code ! X ! R ! DAT (IC50 nM) ! NET (IC50 nM) ! 5-HTT (IC50 nM) ! {{verth|Selectivity ! {{verth|Selectivity | ||||||||
160px | ααRTI-87 | H | 3-methyl-1,2,4-oxadiazole | 204 | 36K | 30K | ||
160px | βαRTI-119 | H | 3-methyl-1,2,4-oxadiazole | 167 | 7K | 41K | ||
160px | αβRTI-124 | H | 3-methyl-1,2,4-oxadiazole | 1028 | 71K | 33K | ||
170px | RTI-125 (32a) | Cl | 3-methyl-1,2,4-oxadiazole | 4.05 ± 0.57 | 363 ± 36 | 2584 ± 800 | 637 | 89.6 |
145px | ββRTI-126Methods for controlling invertebrate pests using cocaine receptor binding ligands. {{US patent|5935953}} (31) | H | 3-methyl-1,2,4-oxadiazole | 100 ± 6 | 7876 ± 551 | 3824 ± 420 | 38.3 | 788 |
170px | RTI-130 (32c) | Cl | 3-phenyl-1,2,4-oxadiazole | 1.62 ± 0.02 | 245 ± 13 | 195 ± 5 | 120 | 151 |
170px | RTI-141 (32d) | Cl | 3-(p-anisyl)-1,2,4-oxadiazole | 1.81 ± 0.19 | 835 ± 8 | 337 ± 40 | 186 | 461 |
170px | RTI-143 (32e) | Cl | 3-(p-chlorophenyl)-1,2,4-oxadiazole | 4.06 ± 0.22 | 40270 ± 180 (4069) | 404 ± 56 | 99.5 | 9919 |
170px | RTI-144 (32f) | Cl | 3-(p-bromophenyl)-1,2,4-oxadiazole | 3.44 ± 0.36 | 1825 ± 170 | 106 ± 10 | 30.8 | 532 |
170px | βRTI-151 (33) | Me | 3-phenyl-1,2,4-oxadiazole | 2.33 ± 0.26 | 60 ± 2 | 1074 ± 130 | 459 | 25.7 |
160px | αRTI-152 | Me | 3-phenyl-1,2,4-oxadiazole | 494 | — | 1995 | ||
170px | RTI-154 (32b) | Cl | 3-isopropyl-1,2,4-oxadiazole | 6.00 ± 0.55 | 135 ± 13 | 3460 ± 250 | 577 | 22.5 |
160px | RTI-155 | Cl | 3-cyclopropyl-1,2,4-oxadiazole | 3.41 | 177 | 4362 |
{{multiple image
| align = center
| perrow = 2
| image1 = RTI-470 structure.png
| width1 = 220
| caption1 = RTI-4229-470 structure. Highly excited 94 pM DAT signal.{{Cite journal
| last1 = Carroll | first1 = F.
| last2 = Howard | first2 = J.
| last3 = Howell | first3 = L.
| last4 = Fox | first4 = B.
| last5 = Kuhar | first5 = M.
| title = Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse
| journal = The AAPS Journal
| volume = 8
| issue = 1
| pages = E196–E203
| year = 2006
| pmid = 16584128
| doi = 10.1208/aapsj080124
| pmc = 2751440
}}
↑ above: 2D skeletal depiction.
↓ below: 3D tube model.
| image3 = RTI-4229-470 with tube model.png
| width3 = 220
| image4 = Heterocyclic tropanes.png
| width4 = 220
| image2 = RTI-371 structure.png
| width2 = 220
}}
class="wikitable sortable sort-under"
|+N-methylphenyltropanes with 1R β,β stereochemistry. ! Structure ! Code ! X ! 2 Group ! DAT (IC50 nM) ! NET (IC50 nM) ! 5-HTT (IC50 nM) ! Selectivity ! Selectivity | ||||||||
150px | RTI-157 | Me | tetrazole | 1557 | >37K | >43K | ||
170px | RTI-163 | Cl | tetrazole | 911 | — | 5456 | ||
170px | RTI-178 | Me | 5-phenyl-oxazol-2-yl | 35.4 | 677 | 1699 | ||
170px | RTI-188 | Cl | 5-phenyl-1,3,4-oxadiazol-2-yl | 12.6 | 930 | 3304 | ||
170px | RTI-189 (32i) | Cl | 5-phenyl-oxazol-2-yl | 19.7 ± 1.98 | 496 ± 42 | 1120 ± 107 | 56.8 | 25.5 |
170px | RTI-194 | Me | 5-methyl-1,3,4-oxadiazol-2-yl | 4.45 | 253 | 4885 | ||
170px | RTI-195 | Me | 5-phenyl-1,3,4-oxadiazol-2-yl | 47.5 | 1310 | >22,000 | ||
170px | RTI-199 | Me | 5-phenyl-1,3,4-thiadiazol-2-yl | 35.9 | >24,000 | >51,000 | ||
170px | RTI-200 | Cl | 5-phenyl-1,3,4-thiadiazol-2-yl | 15.3 | 4142 | >18,000 | ||
170px | RTI-202 | Cl | benzothiazol-2-yl | 1.37 | 403 | 1119 | ||
170px | RTI-219 | Cl | 5-phenylthiazol-2-yl | 5.71 | 8516 | 10,342 | ||
RTI-262 | Cl | 188.2 ± 5.01 | 595.25 ± 5738 | 5207 ± 488 | 316 | 28 | ||
170px | RTI-370 | Me | 3-(p-cresyl)isoxazol-5-yl | 8.74 | 6980 | >100K | ||
170px | RTI-371 | Cl | 3-(p-chlorophenyl)isoxazol-5-yl | 13 | >100K | >100K | ||
170px | RTI-436 | Me| | ||||||
CH=CHPh{{Cite journal| last1 = Carroll | first1 = F.| last2 = Howard | first2 = J.| last3 = Howell | first3 = L.| last4 = Fox | first4 = B.| last5 = Kuhar | first5 = M.| title = Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse| journal = The AAPS Journal| volume = 8| issue = 1| pages = E196–E203| year = 2006| pmid = 16584128 | doi = 10.1208/aapsj080124| pmc = 2751440}} | 3.09 | 1960 (1181) | 335 (31) | |||||
170px | RTI-470 | Cl | o-Cl-benzothiazol-2-yl | 0.094 | 1590 (994) | 1080 (98) | ||
170px | RTI-451 | Me | benzothiazol-2-yl | 1.53 | 476 (287) | 7120 (647) | ||
170px | 32g | 1.28 ± 0.18 | 504 ± 29 | 2420 ± 136 | 1891 | 394 | ||
170px | 32h | 12.6 ± 10.3 | 929 ± 88 | 330 ± 196 | 262 | 73.7 |
File:Heterocyclic phenyltropane syntheses p2.png, Kuhar, et al. {{US patent|5,935,953}} (1999).]]
N.B There are some alternative ways of making the tetrazole ring however; Cf. the sartan drugs synthesis schemes. Bu3SnN3 is a milder choice of reagent than hydrogen azide (cf. Irbesartan).
= Acyl (C2-propanoyl) =
File:WF-23.svg|
File:WF-31.svg|
File:WF-11.svg|
File:WF-33.svg|
File:3ß-(5-Indolyl)-8-azabicyclo(3.2.1)octanes.png|Indolyl{{cite journal|last1=Davies|first1=Huw M.L|last2=Ren|first2=Pingda|last3=Kong|first3=Norman|last4=Sexton|first4=Tammy|last5=Childers|first5=Steven R|title=Synthesis and monoamine transporter affinity of 3β-(4-(2-pyrrolyl)phenyl)-8-azabicyclo[3.2.1]octanes and 3β-(5-Indolyl)-8-azabicyclo[3.2.1]octanes|journal=Bioorganic & Medicinal Chemistry Letters|volume=11|issue=4|year=2001|pages=487–489|issn=0960-894X|doi=10.1016/S0960-894X(00)00701-0|pmid=11229754}}
cf. the Tamagnan series of phenyltropanes for examples with a methylene unit spacer breaking up the indole.
{{sort-under}}
class="wikitable sort-under"
!# | |||||||
WF-23 (39n) | colspan=2|β-naphthyl | C(O)Et | β,β | NMe | 0.115 | 0.394 | No data |
WF-31 PIT | | |||||||
Pri | H | C.O.Et | β,β | NMe | 615 | 54.5 | No data |
WF-11✲ PTT (39e) | Me | H| | |||||
C.O.Et | β,β | NMe | 8.2 | 131 | No data | ||
WF-25 (39a) | H | H| | |||||
C.O.Et | β,β | NMe | 48.3 | 1005 | No data | ||
WF-33 | colspan=2| 6-MeoBN | C(O)Et | α,β | NMe | 0.13 | 2.24 | No data |
colspan=9|✲Compound WF-11 has been shown, under consistent exposure, to elicit a biological response opposite of cocaine i.e. tyrosine hydroxylase gene expression down-regulation (instead of up-regulation as has been observed to be the case for chronic cocaine administration) |
class="wikitable sortable sort-under"
|+2β-acyl-3β-phenyltropane structures{{efn| ←[https://www.erowid.org/archive/rhodium/pdf/cocaineanalogs.pdf#17 Page #941 (17th page of article)] Figure 10}} ! Structure ! S. Singh's ! R1 ! R2 ! DAT [125I]RTI-55 IC50 (nM) ! 5-HTT [3H]Paroxetine Ki (nM) ! Selectivity 5-HTT/DAT | ||||||
cocaine | 173 ± 19 | — | — | |||
Troparil 11a (WIN 35065–2) | 98.8 ± 12.2 | — | — | |||
x100px | WF-25 39a | C2H5 | C6H5 | 48.3 ± 2.8 | 1005 ± 112 | 20.8 |
x100px | 39b | CH3 | C6H5 | 114 ± 22 | 1364 ± 616 | 12.0 |
x100px | 39c | C2H5 | C6H4-4-F | 15.3 ± 2.8 | 630 ± 67 | 41.2 |
x100px | 39d | CH3 | C6H4-4-F | 70.8 ± 13 | 857 ± 187 | 12.1 |
rowspan=3|x100px | WF-11 39e | C2H5 | C6H4-4-CH3 | 8.2 ± 1.6 | 131 ± 1 | 16.0 |
(+)-39e | C2H5 | C6H4-4-CH3 | 4.21 ± 0.05 | 74 ± 12 | 17.6 | |
(-)-39e | C2H5 | C6H4-4-CH3 | 1337 ± 122 | >10000 | — | |
x100px | 39f | CH3 | C6H4-4-CH3 | 9.8 ± 0.5 | 122 ± 22 | 12.4 |
x100px | 39g | CH3 | C6H4-4-C2H5 | 152 ± 24 | 78.2 ± 22 | 0.5 |
x100px | 39h | C2H5 | C6H4-4-CH(CH3)2 | 436 ± 41 | 35.8 ± 4.4 | 0.08 |
x100px | 39i | C2H5 | C6H4-4-C(CH3)3 | 2120 ± 630 | 1771 ± 474 | 0.8 |
x100px | 39j | C2H5 | C6H4-4-C6H5 | 2.29 ± 1.08 | 4.31 ± 0.01 | 1.9 |
x130px | 39k | C2H5 | C6H4-2-CH3 | 1287 ± 322 | 710000 | >7.8 |
x130px | 39l | C2H5 | 1-naphthyl | 5.43 ± 1.27 | 20.9 ± 2.9 | 3.8 |
x130px | 39m | CH3 | 1-naphthyl | 10.1 ± 2.2 | 25.6 ± 5.1 | 2.5 |
x100px | WF-23 39n | C2H5 | 2-naphthyl | 0.115 ± 0.021 | 0.394 ± 0.074 | 3.5 |
x100px | 39o | CH3 | 2-naphthyl | 0.28 ± 0.11 | 1.06 ± 0.36 | 3.8 |
x100px | 39p | C2H5 | C6H4-4-CH(C2H5)2 | 270 ± 38 | 540 ± 51 | 2.0 |
x100px | 39q | C2H5 | C6H4-4-C6H11 | 320 ± 55 | 97 ± 12 | 0.30 |
x100px | 39r | C2H5 | C6H4-4-CH=CH2 | 0.90 ± 0.34 | 3.2 ± 1.3 | 3.5 |
x100px | 39s | C2H5 | C6H4-4-C(=CH2)CH3 | 7.2 ± 2.1 | 0.82 ± 0.38 | 0.1 |
== 2β-Acyl-3β-naphthyl substituted ==
class="wikitable sortable sort-under"
|+2β-Acyl-3β-(substituted naphthyl)-8-azabicyclo ! Structure ! Short Assignation ! R ! DAT ! SERT ! NET ! potency ratio ! potency ratio | |||||||
File:WF-11.svg | WF-11 (6) | 4′-Me | 8.2 ± 1.6 | 131 ± 10 | 65 ± 9.2 | 0.06 | 0.5 |
File:WF-31.svg | WF-31 (7) | 4′-iPr | 436 ± 41 | 36 ± 4 | >10,000 | 12 | >250 |
File:WF-23.svg | WF-23 (8) | 2-naphthalene | 0.12 ± 0.02 | 0.39 ± 0.07 | 2.9 ± 0.5 | 0.3 | 7 |
x150px | 2β-acyl-3β-1-naphthalene (9a) | 4′-H | 5.3 ± 1.3 | 21 ± 2.9 | 49 ± 10 | 0.3 | 18 |
x150px | (9b) | 4′-Me | 25.1 ± 0.5 | 8.99 ± 1.70 | 163 ± 36 | 3 | 18 |
x150px | (9c) | 4′-Et | 75.1 ± 11.9 | 175 ± 25 | 4769 ± 688 | 0.7 | 27 |
x150px | (9d) | 4′-iPr | 225 ± 36 | 136 ± 64 | >10,000 | 2 | >73.5 |
x110px | (10a) | 6′-Et | 0.15 ± 0.04 | 0.38 ± 0.19 | 27.7 ± 9.6 | 0.4 | 74 |
x110px | (10b) | 6′-iPr | 0.39 ± 0.04 | 1.97 ± 0.33 | no data | 0.2 | — |
x110px | (10ce) | 6′- OMe | 0.13 ± 0.04 | 2.24 ± 0.34 | no data | 0.05 | — |
x110px | (10d) | 5′-Et, 6′-OMe | 30.8 ± 6.6 | 7.55 ± 1.57 | 3362 ± 148 | 4.1 | 445 |
x110px | (10e) | 5′-C(Me)=CH2, 6′-OMe | 45.0 ± 3.7 | 88.0 ± 13.3 | 2334 ± 378 | 0.5 | 26.5 |
x110px | (10f) | 6′-I | 0.35 ± 0.07 | 0.37 ± 0.02 | no data | 1.0 | — |
x120px | (10g) | 7′-I | 0.45 ± 0.05 | 0.47 ± 0.02 | no data | 0.5d | — |
x110px | (10h) | 5′-NO2, 6′-OMe | 148 ± 50 | 15 ± 1.6 | no data | 10 | — |
x110px | (10i) | 5′-I, 6′-OMe | 1.31 ± 0.33 | 2.27 ± 0.31 | 781 ± 181 | 0.6 | 344 |
x110px | (10j) | 5′-COMe, 6′-OMe | 12.6 ± 3.8 | 15.8 ± 1.65 | 498 ± 24 | 0.8 | 32 |
x145px | (11a) | 2β-COCH3, 1-naphthyl | 10 ± 2.2 | 26 ± 5.1 | 165 ± 40 | 0.4 | 6.3 |
x135px | (11b) | 2α-COCH3, 1-naphthyl | 97 ± 21 | 217 ± 55 | no data | 0.45 | — |
x120px | (11c) | 2α-COCH2CH3, 2-naphthyl | 2.51 ± 0.82 | 16.4 ± 2.0 | 68.0 ± 10.8 | 0.15 | 4.1 |
x110px | (11d) | 2β-COCH3, 2-naphthyl | 1.27 ± 0.15 | 1.06 ± 0.36 | 4.9 ± 1.2 | 1.2 | 4.6 |
x110px | (11e) | 2β-COCH(CH3)2, 2-naphthyl | 0.25 ± 0.08 | 2.08 ± 0.80 | 37.6 ± 10.5 | 0.12 | 18.1 |
x110px | (11f) 79a | 2β-COCH2CH3, 2-naphthyl, N8-demethyl | 0.03 ± 0.01 | 0.23 ± 0.07 | 2.05 ± 0.9 | 0.13 | 8.9 |
* ɑ nonspecific binding was determined in the presence of 1.0 μM WF-23 (source equates WF-23 as analogue 3a, but table gives # as analogue 8)
|
|
= Ester reduction =
Note: p-fluorophenyl is weaker than the others. RTI-145 is not peroxy, it is a methyl carbonate.
class="wikitable"
!Code!!X!!2 Position!!config!!8!! DA !! 5-HT !! NE | |||||
RTI-100 | F | | ||||
CH2OH | β,β | NMe | 47 | 4741 | no data |
RTI-101 | I | | ||||
CH2OH | β,β | NMe | 2.2 | 26 | no data |
RTI-99 | Br | | ||||
CH2OH | β,β | NMe | 1.49 | 51 | no data |
RTI-93 | Cl | | ||||
CH2OH | β,β | NMe | 1.53 | 204 | 43.8 |
RTI-105 | Cl | | ||||
CH2OAc | β,β | NMe | 1.60 | 143 | 127 |
RTI-123 | Cl | | ||||
CH2OBz | β,β | NMe | 1.78 | 3.53 | 393 |
RTI-145 | Cl| | ||||
CH2OCO2Me | β,β | NMe | 9.60 | 2.93 | 1.48 |
= 2-Alkane/Alkene =
class="wikitable sortable"
|+ 2-Alkane/Alkene-3-Phenyltropanes ! Structure ! Singh's # ! R ! X ! DAT ! DA uptake ! 5-HT Uptake ! Selectivity | |||||||
File:WIN 35,065-2.svg | 11a WIN 35062-2 | 89.4 | 53.7 | 186 | 0.6 | ||
File:Chlorophenyltropane.png | 11c | 0.83 ± 00.7 | 28.5 ± 0.9 | — | 34.3 | ||
File:RTI-32 structure.png | 11f | 5.76 | 6.92 | 23.2 | 1.2 | ||
File:Cocaine analog 41a.svg | 41a | (CH2)2CH3 | H | 12.2 | 6.89 | 86.8 | 0.6 |
File:Cocaine analog 41b.svg | 41b | (CH2)3C6H5 | H | 16 ± 2a | 43 ± 13b | — | 2.7 |
File:Cocaine analog 42.svg | 42 | (CH2)2CH3 | F | 5.28 | 1.99 | 21.7 | 0.4 |
File:Cocaine analog 43a.svg | 43a | CH=CH2 | Cl | 0.59 ± 0.15 | 2.47 ± 0.5 | — | 4.2 |
File:Cocaine analog 43b.svg | 43b | E-CH=CHCl | Cl | 0.42 ± 0.04 | 1.13 ± 0.27 | — | 2.7 |
File:Cocaine analog 43c.svg | 43c | Z-CH=CHCl | Cl | 0.22 ± 0.02 | 0.88 ± 0.05 | — | 4.0 |
File:Cocaine analog 43d.svg | 43d | E-CH=CHC6H5 | Cl | 0.31 ± 0.04 | 0.66 ± 0.01 | — | 2.1 |
File:Cocaine analog 43e.svg | 43e | Z-CH=CHC6H5 | Cl | 0.14 ± 0.07 | 0.31 ± 0.09 | — | 2.2 |
File:Cocaine analog 43f.svg | 43f | CH2CH3 | Cl | 2.17 ± 0.20 | 2.35 ± 0.52 | — | 1.1 |
File:Cocaine analog 43g.svg | 43 g | (CH2)2CH3 | Cl | 0.94 ± 0.08 | 1.08 ± 0.05 | — | 1.1 |
File:Cocaine analog 43h.svg | 43h | (CH2)3CH3 | Cl | 1.21 ± 0.18 | 0.84 ± 0.05 | — | 0.7 |
File:Cocaine analog 43i.svg | 43i | (CH2)5CH3 | Cl | 156 ± 15 | 271 ± 3 | — | 1.7 |
File:Cocaine analog 43j.svg | 43j | (CH2)2C6H5 | Cl | 1.43 ± 0.03 | 1.54 ± 0.08 | — | 1.0 |
File:Cocaine analog 44a.svg | 44a | (CH2)2CH3 | CH3 | 1.57 | 1.10 | 10.3 | 0.7 |
File:Cocaine analog 44b.svg | 44b | (CH2)3CH3 | CH3 | 1.82 | 1.31 | 15.1 | 0.7 |
File:Cocaine analog 45.svg | 45 | (CH2)2CH3 | H | 74.9 | 30.2 | 389 | 0.4 |
File:Cocaine analog 46.svg | 46 | (CH2)2CH3 | F | 21.1 | 12.1 | 99.6 | 0.6 |
File:Cocaine analog 47a.svg | 47a | (CH2)2CH3 | CH3 | 8.91 | 11.8 | 50.1 | 1.3 |
File:Cocaine analog 47b.svg | 47b | (CH2)3CH3 | CH3 | 11.4 | 10.1 | 51.0 | 0.9 |
aKi value for displacement of WIN 35428.
bIC50 value.
{{multiple image
| align = left
| direction = horizontal
| header = Compound 48
| image1 = Compound 48-H.svg
| width1 = 220
| caption1 = para-hydro
| image2 = Compound 48-Cl.svg
| width2 = 260
| caption2 = para-chloro
}}
{{clear}}
= Irreversible covalent (''cf.'' ionic) C2 ligands =
Irreversible (phenylisothiocyanate) binding ligand ({{Cite journal
| last1 = Murthy | first1 = V.
| last2 = Martin | first2 = T. J.
| last3 = Kim | first3 = S.
| last4 = Davies | first4 = H. M. L.
| last5 = Childers | first5 = S. R.
| title = In Vivo Characterization of a Novel Phenylisothiocyanate Tropane Analog at Monoamine Transporters in Rat Brain
| doi = 10.1124/jpet.108.138842
| journal = Journal of Pharmacology and Experimental Therapeutics
| volume = 326
| issue = 2
| pages = 587–595
| year = 2008
| pmid = 18492949
| s2cid = 5996473
| pmid = 1588560
| year = 1992
| last1 = Carroll | first1 = F. I.
| last2 = Gao
| last3 = Abraham
| last4 = Lewin
| last5 = Lew
| last6 = Patel
| last7 = Boja
| last8 = Kuhar
| title = Probes for the cocaine receptor. Potentially irreversible ligands for the dopamine transporter
| volume = 35
| issue = 10
| pages = 1813–1817
| journal = Journal of Medicinal Chemistry
| doi = 10.1021/jm00088a017
| author1 = Wu| first2 = M.| first3 = Q.| first4 = C.| first5 = F.| first6 = P.
| title = Concurrent autoreceptor-mediated control of dopamine release and uptake during neurotransmission: an in vivo voltammetric study
| journal = Journal of Neuroscience
| volume = 22
| issue = 14
| pages = 6272–6281
| year = 2002
| pmid = 12122086
| pmc = 6757948| last2 = Reith
| last3 = Walker
| last4 = Kuhn
| last5 = Carroll
| last6 = Garris
| doi = 10.1523/JNEUROSCI.22-14-06272.2002}} 4′-isothiocyanatophenyl (1R,2S,3S,5S)-3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate. Also known as: 3β-(p-chlorophenyl)tropan-2β-carboxylic acid p-isothiocyanatophenylmethyl ester.
==C2 Acyl, N8 phenylisothiocyanate==
Note the contrast to the phenylisothiocyanate covalent binding site locations as compared to the one on p-Isococ, a non-phenyltropane cocaine analogue.
= Benztropine based (C2-position hetero-substituted) phenyltropanes =
= F&B series (Biotin side-chains etc.) =
One patent claims a series of compounds with biotin-related sidechains are pesticides.
class="talk collapsed collapsible" |
Images of the biotin C2 side-chained phenyltropanes, click to |
---|
style="text-align: left;"
| |
class="wikitable"
!Structure!!Code!!para-X!!C2-Tropane Position!!config!! DA !! NE!! 5-HT | |||||||
x150px | — | H | F1 | β,β | — | — | — |
x140px | RTI-224 | Me | F1c | β,β | 4.49 | — | 155.6 |
x160px | RTI-233 | Me | F2 | β,β | 4.38 | 516 | 73.6 |
x160px | RTI-235 | Me | F3d | β,β | 1.75 | 402 | 72.4 |
x150px | — | — | F3 | β,β | — | — | — |
x140px | RTI-236 | Me | B1d | β,β | 1.63 | 86.8 | 138 |
x140px | RTI-237 | Me | B2d | β,β | 7.27 | 258 | 363 |
x160px | RTI-244 | Me | B3d | β,β | 15.6 | 1809 | 33.7 |
x140px | RTI-245 | Cl | F4c | β,β | 77.3 | — | — |
RTI-246 | Me | F4c | β,β | 50.3 | 3000 | — | |
x150px | — | — | F5 | β,β | — | — | — |
x120px | RTI-248 | Cl | F6c | β,β | 9.73 | 4674 | 6.96 |
x140px | RTI-249 | Cl | F1c | β,β | 8.32 | 5023 | 81.6 |
RTI-266 | Me | F2 | β,β | 4.80 | 836 | 842 | |
RTI-267 | Me | F7 wrong | β,β | 2.52 | 324 | 455 | |
x210px | RTI-268 | Me | F7 right | β,β | 3.89 | 1014 | 382 |
x220px | RTI-269 | Me | F8 | β,β | 5.55 | 788 | 986 |
= Miscellany (''i.e.'' Misc./Miscellaneous) C2-substituents =
File:Phenyltropane FMOC-hydrazide.svg
File:Phenyltropane dimethylaminonaphthalene.svg
File:Phenyltropane pyrene hydroxamide.svg
class="wikitable"
!Structure!!Code!!X!!2 Position!!config!!8!! DA !! 5-HT !! NE | ||||||||
170px | RTI-102 | I | CO2H | β,β | NMe | 474 | 1928 | 43,400 |
170px | RTI-103 | Br | CO2H | β,β | NMe | 278 | 3070 | 17,400 |
170px | RTI-104 | F | CO2H | β,β | NMe | 2744 | >100K | >100K |
170px | RTI-108 | Cl | | ||||||
CH2Cl | β,β | NMe | 2.64 | 98 | 129.8 | |||
170px | RTI-241 | Me | | ||||||
CH2CO2Me | β,β | NMe | 1.02 | 619 | 124 | |||
170px | RTI-139 | Cl | | ||||||
CH3 | β,β | NMe | 1.67 | 85 | 57 | |||
170px | RTI-161 | Cl | | ||||||
C≡N | β,β | NMe | 13.1 | 1887 | 2516 | |||
170px | RTI-230 | Cl | H3C–C=CH2 | β,β | NMe | 1.28 | 57 | 141 |
170px | RTI-240 | Cl | | ||||||
CHMe2 | β,β | NMe | 1.38 | 38.4 | 84.5 | |||
170px | RTI-145 | Cl | | ||||||
CH2OCO2Me | β,β | NMe | 9.60 | 2,932 | 1,478 | |||
170px | RTI-158 | Me | | ||||||
C≡N | β,β | NMe | 57 | 5095 | 1624 | |||
170px | RTI-131 | Me | | ||||||
CH2NH2 | β,β | NMe | 10.5 | 855 | 120 | |||
170px | RTI-164 | Me | | ||||||
CH2NHMe | β,β | NMe | 13.6 | 2246 | 280 | |||
170px | RTI-132 | Me | | ||||||
CH2NMe2 | β,β | NMe | 3.48 | 206 | 137 | |||
170px | RTI-239 | Me | | ||||||
CHMe2 | β,β | NMe | 0.61 | 114 | 35.6 | |||
180px | RTI-338 | Et | | ||||||
CO2CH2Ph | β,β | NMe | 1104 | 7.41 | 3366 | |||
150px | RTI-348 | H | | ||||||
Ph | β,β | NMe | 28.2 | >34,000 | 2670 |
C2-truncated/descarboxyl (non-ecgonine w/o 2-position-replacement tropanes)
= Aryl-Tropenes =
{{Cite patent |country= WO |number= 2004113297|title=Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors|pubdate=2004-12-29|assign=NeuroSearch AS|inventor1-last=Peters|inventor1-first=Dan |inventor2-last= Olsen|inventor2-first=Gunnar M.|inventor3-last=Nielsen|inventor3-first=Elsebet Oestergaard |inventor4-last=Scheel-Krueger|inventor4-first=Joergen}}
class="wikitable"
!Test compound!!DA-uptake IC50(μM)!!NA-uptake IC50(μM)!! 5-HT-uptake IC50(μM) | |||
(+)-3-(4-Chlorophenyl)-8-H-aza-bicyclo[3.2.1]oct-2-ene | 0.26 | 0.028 | 0.010 |
(+)-3-Napthalen-2-yl-8-azabicyclo[3.2.1]oct-2-ene | 0.058 | 0.013 | 0.00034 |
(–)-8-Methyl-3-(naphthalen-2-yl)-8-azabicylo[3.2.1]oct-2-ene | 0.034 | 0.018 | 0.00023 |
class="wikitable" style="text-align:center"
|+ 8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES | |||
Test Compound
! DA uptake IC50(μM) ! NE uptake IC50(μM) ! 5-HT uptake IC50(μM) | |||
---|---|---|---|
(±)-3-(3,4-Dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene | 0.079 | 0.026 | 0.0047 |
{{US patent|2001047028}}
class="wikitable" | |||
Test Compound
! DA uptake IC50(μM) ! NE uptake IC50(μM) ! 5-HT uptake IC50(μM) | |||
---|---|---|---|
(±)-3-(4-cyanophenyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene | 18 | 4.9 | 0.047 |
(±)-3-(4-nitrophenyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene | 1.5 | 0.5 | 0.016 |
(±)-3-(4-trifluoromethoxyphenyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene | 22.00 | 8.00 | 0.0036 |
Enantioselective nonstandard configurations (non-2β-,3β-)
= β,α Stereochemistry =
class="wikitable"
!Structure 100px!!Compound | ||||||||||
100px | RTI-140 20a | H | CO2Me | β,α | NMe | 101 ± 16 | 5,701 ± 721 | 2,076 ± 285 | 56.4 | 20.6 |
100px | RTI-352ɑ 20d | I | CO2Me | β,α | NMe | 2.86 ± 0.16 | 64.9 ± 1.97 | 52.4 ± 4.9 | 22.8 | 18.4 |
100px | RTI-549 | Br | CO2Me | β,α | NMe | — | — | — | — | — |
100px | RTI-319b | 3α-2-naphthyl | CO2Me | β,α | NMe | 1.1 ± 0.09 | 11.4 ± 1.3 | 70.2 ± 6.28 | — | — |
100px | RTI-286c 20b | F | CO2Me | β,α | NMe | 21 ± 0.57 | 5062 ± 485 | 1231 ± 91 | 241 | 58.6 |
140px | RTI-274d | F | CH2O(3′,4′-MD-phenyl) | β,α | NH | 3.96 | 5.62 | 14.4 | — | — |
100px | RTI-287 | Et | CO2Me | β,α | NMe | 327 | 1687 | 17,819 | — | — |
100px | 20c | Cl | CO2Me | β,α | NMe | 2.4 ± 0.2 | 998 ± 120 | 60.1 ± 2.4 | 416 | 25.0 |
100px | 20e | Me | CO2Me | β,α | NMe | 10.2 ± 0.08 | 4250 ± 422 | 275 ± 24 | 417 | 27.0 |
120px | Bn | CO2Me | β,α | NMe | — | — | — | — | — |
{{center|ɑ{{US Patent|6358492}}b{{US Patent|7011813}}c{{US Patent|7011813}}d{{US Patent|7291737}}}}
= α,β Stereochemistry =
{{Cite patent|country=CA|number=2112084}}
File:Brasofensine.svg
File:Tesofensine chemical structure.png
File:NStwothreefivenine.png
class="wikitable"
!Compound!!DA (μM)!!M.E.D. (mg/kg)!!Dose (mg/kg)!!Activity !!Activity | |||||
(2R,3S)-2-(4-chlorophenoxymethyl)-8-methyl-3-(3-chlorophenyl)-8-azabicyclo[3.2.1]octane | 0.39 | <1 | 50 | 0 | 0 |
(2R,3S)-2-(carboxymethyl)-8-methyl-3-(2-naphthyl)-8-azabicyclo[3.2.1]octane | 0.1 | 1 | 25 | 0 | 0 |
(2R,3S)-2-(carboxymethyl)-8-methyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane | 0.016 | 0.25 | 50 | + | +++ |
== di-chloro; ''para''- & ''meta''- in tandem (α,β configured phenyltropanes) ==
{{US patent|2001047028}}
class="wikitable"
!Compound!!X!!2 Group!!config!!8!! DA!!5-HT!!NE | |||||||
Brasofensine | Cl2 | methyl aldoxime | α,β | NMe | — | — | — |
Tesofensine | Cl2 | ethoxymethyl | α,β | NMe | 65 | 11 | 1.7 |
NS-2359 (GSK-372,475) | Cl2 | Methoxymethyl | α,β | NH | — | — | — |
== fumaric acid salts (of α,β configured phenyltropanes) ==
{{Cite patent|country=WO|number=2004072075|title=Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
|pubdate=2004-08-26|assign=NeuroSearch AS|inventor1-last=Peters|inventor1-first=Dan |inventor3-last= Olsen|inventor3-first=Gunnar M.|inventor2-last=Nielsen|inventor2-first=Elsebet Oestergaard |inventor4-last=Scheel-Krueger|inventor4-first=Joergen}}
class="wikitable" | |||
Test Compound
! DA uptake IC50(μM) ! NE uptake IC50(μM) ! 5-HT uptake IC50(μM) | |||
---|---|---|---|
(2R,3S)-2-(2,3-dichlorophenoxymethyl)-8-methyl-3-(3-chlorophenyl)-8-azabicyclo[3.2.1]octane fumaric acid salt | 0.062 | 0.035 | 0.00072 |
(2R,3S)-2-(Naphthaleneoxymethane)-8-methyl-3-(3-chlorophenyl)-8-azabicyclo[3.2.1]octane fumaric acid salt | 0.062 | 0.15 | 0.0063 |
(2R,3S)-2-(2,3-dichlorophenoxymethyl)-8-H-3-(3-chlorophenyl)-8-azabicyclo[3.2.1]octane fumaric acid salt | 0.10 | 0.048 | 0.0062 |
(2R,3S)-2-(Naphthlyloxymethane)-8-H-3-(3-chlorophenyl)-8-azabicyclo[3.2.1]octane fumaric acid salt | 0.088 | 0.051 | 0.013 |
Arene equivalent alterations
= ''η''<sup>6</sup>-3β-(transition metal complexed phenyl)tropanes =
File:Cocaine analog 21ab alternate.pngs and perrhenate by a double ligand transfer (DLT) reaction.{{cite journal | pmid = 11792176 | volume=13 | issue=1 | title=Synthesis of cyclopentadienyltricarbonyl rhenium phenyltropanes by double ligand transfer: organometallic ligands for the dopamine transporter | journal=Bioconjug Chem | pages=29–39 | last1 = Cesati | first1 = RR 3rd | last2 = Tamagnan | first2 = G | last3 = Baldwin | first3 = RM | last4 = Zoghbi | first4 = SS | last5 = Innis | first5 = RB | last6 = Kula | first6 = NS | last7 = Baldessarini | first7 = RJ | last8 = Katzenellenbogen | first8 = JA | doi=10.1021/bc010011x | year=2002}}]]
Unlike metal complexed PTs created with the intention of making useful radioligands, 21a & 21b were produced seeing as their η6-coordinated moiety dramatically altered the electronic character and reactivity of the benzene ring, as well as such a change adding asymmetrical molecular volume to the otherwise planar arene ring unit of the molecule. (cf. the Dewar–Chatt–Duncanson model). In addition the planar dimension of the transition metal stacked arene becomes delocalized (cf. Bloom and Wheeler.{{cite journal | journal = Angew. Chem. | year = 2011 | volume = 123 | pages = 7993–7995 | doi = 10.1002/ange.201102982 | title = Taking the Aromaticity out of Aromatic Interactions | last1 = Bloom | first1 = Jacob W. G. | last2 = Wheeler | first2 = Steven E. | issue = 34| bibcode = 2011AngCh.123.7993B }}).
21a was twice as potent as both cocaine and troparil in displacement of β-CFT, as well as displaying high & low affinity Ki values in the same manner as those two compounds. Whereas its inhibition of DA uptake showed it as comparably equipotent to cocaine & troparil. 21b by contrast had a one hundredfold decrease in high-affinity site binding compared to cocaine and a potency 10× less for inhibiting DA uptake. Attesting these as true examples relating useful effective applications for bioorganometallic chemistry.
File:Cocaine analog 21a alternate.png containing phenyltropane, having roughly twice the strength Ki affinity as parent compound at same mean affect.]]
The discrepancy in binding for the two benzene metal chelates is assumed to be due to electrostatic differences rather than their respective size difference. The solid cone angles, measured by the steric parameter (i.e. θ) is θ=131° for Cr(CO)3 whereas Cp*Ru was θ=187° or only 30% larger. The tricarbonyl moiety being considered equivalent to the cyclopenta dienyl (Cp) ligand.
File:Cocaine analog 21b alternate.png
class="wikitable sortable"
|+Displacement of Receptor-Bound [3H]WIN 35428 and Inhibition of [3H]DA Uptake by Transition Metal Complexes of 3β-Phenyltropanes ! Structure ! Compound # ! Ki (nM)ɑ ! IC50 (nM) ! selectivity | ||||
File:Cocaine analog 21a.svg | 21ac | 17 ± 15b 224 ± 83 | 418 | 24.6 |
File:Cocaine analog 21b.svg | 21bd | 2280 ± 183 | 3890 | 1.7 |
colspan="2"|Cocaine | 32 ± 5 388 ±221 | 405 | 12.6 | |
colspan="2"|Troparil (11a) | 33 ± 17 314 ± 222 | 373 | 11.3 |
- ɑThe binding data fit a two-site model better than a one-site model
- bThe Ki value for the one-site model was 124 ± 10 nM
- cIUPAC:
[ η6-(2β-carbomethoxy-3β-phenyl)tropane] tricarbonylchromium - dIUPAC:
[ η5-(pentamethylcyclopentadienyl)] -[ η6-(2β-carbomethoxy-3β-phenyl)tropane] ruthenium-(II) triflate
= 3-(2-thiophene) and 3-(2-furan) =
File:Cocaine analogs - thiophenes and furans.svg
{{Clear}}
class="wikitable"
! Code!!Compound!!DA (μM)!!NE (μM)!!5-HT (μM) | ||||
1 | (2R,3S)-2-(2,3-Dichlorophenoxymethyl)-8-methyl-3-(2-thienyl)-8-aza-bicyclo[3.2.1]octanefumaric acid salt | 0.30 | 0.0019 | 0.00052 |
2 | (2R,3S)-2-(1-Naphthyloxymethyl)-8-methyl-3-(2-thienyl)-8-aza-bicyclo-[3.2.1]octane fumaric acid salt | 0.36 | 0.0036 | 0.00042 |
3 | (2R,3S)-2-(2,3-Dichlorophenoxymethyl)-8-methyl-3-(2-furanyl)-8-aza-bicyclo-[3.2.1]octane fumaric acid salt | 0.31 | 0.00090 | 0.00036 |
4 | (2R,3S)-2-(1-Naphthyloxymethyl)-8-methyl-3-(2-furanyl)-8-aza-bicyclo-[3.2.1]octane fumaric acid salt | 0.92 | 0.0030 | 0.00053 |
5 | (2R,3S)-2-(2,3-Dichlorophenoxymethyl)-8-H-3-(2-thienyl)-8-aza-bicyclo[3.2.1]octane fumaric acid salt | 0.074 | 0.0018 | 0.00074 |
6 | (2R,3S)-2-(1-Naphthyloxymethyl)-8-H-3-(2-thienyl)-8-aza-bicyclo[3.2.1]octane fumaric acid salt | 0.19 | 0.0016 | 0.00054 |
= Thiophenyltropanes =
= Diaryl =
File:Hanna et al.png|Fluoxetine homologue,[http://www.pubfacts.com/detail/23022052/A-novel-spirocyclic-tropanyl-%CE%94%C2%B2-isoxazoline-derivative-enhances-citalopram-and-paroxetine-binding- A novel spirocyclic tropanyl-Δ2-isoxazoline derivative enhances citalopram and paroxetine binding to serotonin transporters as well as serotonin uptake.] Bioorg Med Chem 2012 Nov 10;20(21):6344-55. Epub 2012 Sep 10. also: Hanna et al. (2007){{cite journal | doi = 10.1016/j.bmc.2007.08.055 | pmid=17870537 | title=Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin | journal=Bioorganic | date=2007 | volume=15 | issue=24 | pages=7765–7772 | first=Mona M. | last=Hanna}}
cf. the paroxetine homologue PTs
6/7-tropane position substituted
= 2β-carbomethoxy 6/7 substituted =
class="wikitable sortable"
|+6/7-Substituted 2-carbomethoxy-phenyltropanes ! Structure ! Compound # ! Substitution ! DAT (IC50 nM) ! 5-HTT (IC50 nM) ! Selectivity | |||||
Cocaine | H | 65 ± 12| | |||
160px | 103a | 3β,2β, 7-OMe 3′,4′-Cl2 | 86 ± 4.7 | 884 ± 100 | 10.3 |
160px | 103b | 3β,2β, 7-OH 3′,4′-Cl2 | 1.42 ± 0.03 | 28.6 ± 7.8 | 20.1 |
130px | 103c | 3α,2β, 7-OH 3′,4′-Cl2 | 1.19 ± 0.16 | 1390 ± 56 | 1168 |
160px | 104a | 3β,2β, 6-OH 4′-Me | 215ɑ| | ||
160px | 104b | 3β,2α, 6-OH 4′-Me | 15310ɑ| | ||
130px | 104c | 3α,2β, 6-OH 4′-Me | 930ɑ| | ||
130px | 104d | 3α,2α, 6-OH 4′-Me | 7860ɑ| | ||
- ɑIC50 value for displacement of [H3]mazindol. IC50 for cocaine 288 nM for displacement of [H3]mazindol
= 3-butyl 6/7 substituted =
class="wikitable sortable"
|+6/7-Substituted 3-butyl-phenyltropanes ! Structure ! Compound # ! Substituent ! Ki nM ! Ki nM ! Selectivity | |||||
Cocaine | H | 270 ± 0.03 | 400 ± 20 | 1.5 | |
x70px | 121a | 7β-CN | 2020 ± 10 | 710 ± 40 | 0.3 |
x70px | 121b | 6β-CN | 3040 ± 480 | 6030 ± 880 | 2.0 |
x70px | 121c | 7β-SO2Ph | 4010 ± 310 | 8280 ± 1340 | 2.1 |
x90px | 121d | 6β-SO2Ph | 4450 ± 430 | 8270 ± 690 | 1.8 |
x80px | 121e | 7α-OH | 830 ± 40 | 780 ± 60 | 0.9 |
x130px | 121f | H | 100 ± 10 | 61 ± 10 | 0.6 |
x130px | 121g | 7β-CN | 24000 ± 3420 | 32100 ± 8540 | 1.3 |
x130px | 121h | 6β-CN | 11300 ± 1540 | 26600 ± 3330 | 2.3 |
x130px | 121i | 7β-SO2Ph | 7690 ± 2770 | 7050 ± 450 | 0.9 |
x130px | 121j | 6β-SO2Ph | 4190 ± 700 | 8590 ± 1360 | 2.0 |
x130px | 121k | 7α-SO2Ph | 3420 ± 1100| | ||
x130px | 121l | 7β-SO2Ph, 7α-F | 840 ± 260 | 2520 ± 290 | 3.0 |
x130px | 121m | 7α-F | 200 ± 10 | 680 ± 10 | 3.4 |
x130px | 121n | 7β-F | 500 ± 10 | 550 ± 140 | 1.1 |
= intermediate 6- & 7-position synthesis modified phenyltropanes =
class="wikitable sortable"
! Structure ! Compound # ! Substituent W ! Substituent X ! Substituent Y ! Substituent Z | |||||
x120px | (±)-122a | CN | H | H | H |
x120px | (±)-122b | H | H | CH | H |
x120px | (±)-122c | H | CH | H | H |
x120px | (±)-122d | H | H | H | CH |
x120px | (±)-122e | SO2Ph | H | H | H |
x120px | (±)-122f | H | H | SO2Ph | H |
x120px | (±)-122g | H | SO2Ph | H | H |
x120px | (±)-122h | SO2Ph | F | H | H |
x120px | (±)-122i | F | SO2Ph | H | H |
x120px | (±)-122j | H | H | SO2Ph | F |
8-tropane (bridgehead) position modified
= Nortropanes (''N''-demethylated) =
File:NStwothreefivenine.png (GSK-372,475)]]
It is well established that electrostatic potential around the para position tends to improve MAT binding. This is believed to also be the case for the meta position, although it is less studied. N-demethylation dramatically potentiates NET and SERT affinity, but the effects of this on DAT binding are insignificant.{{Cite journal
| last2 = Abraham
| last6 = Carroll | first1 = B. | first2 = P. | first3 = A.
| last4 = Kuhar
| last3 = Lewin| first4 = M.
| last1 = Blough | first5 = J. | first6 = F.
| last5 = Boja
| title = Synthesis and transporter binding properties of 3β-(4′-alkyl-, 4′-alkenyl-, and 4′-alkynylphenyl)nortropane-2β-carboxylic acid methyl esters: serotonin transporter selective analogs
| journal = Journal of Medicinal Chemistry
| volume = 39
| issue = 20
| pages = 4027–4035
| year = 1996
| pmid = 8831768
| doi = 10.1021/jm960409s
| s2cid = 21616809 }} Of course, this is not always the case. For an interesting exception to this trend, see the Taxil document. There is ample evidence suggesting that N-demethylation of alkaloids occurs naturally in vivo via a biological enzyme. The fact that hydrolysis of the ester leads to inactive metabolites means that this is still the main mode of deactivation for analogues that have an easily metabolised 2-ester substituent. The attached table provides good illustration of the effect of this chemical transformation on MAT binding affinities. N.B. In the case of both nocaine and pethidine, N-demethyl compounds are more toxic and have a decreased seizure threshold.{{Cite journal
| pmid = 7205634
| date=Mar 1981 | last1 = Spealman | first1 = R. D.
| last2 = Kelleher | first2 = R. T.
| title = Self-administration of cocaine derivatives by squirrel monkeys
| volume = 216
| issue = 3
| pages = 532–536
| issn = 0022-3565
| journal = The Journal of Pharmacology and Experimental Therapeutics
}}
class="wikitable sortable"
|+Selected ββ Nortropanes ! Code ! X ! DA ! 5HT ! NE | ||||
RTI-142 75b | F | 4.39 | 68.6 | 18.8 |
RTI-98 75d Norɑ-RTI-55 | I | 0.69 | 0.36 | 11.0 |
RTI-110 75c | Cl | 0.62 | 4.13 | 5.45 |
RTI-173 75f | Et | 49.9 | 8.13 | 122 |
RTI-279 Norɑ-RTI-280 | para-Me meta-I | 5.98 ± 0.48 | 1.06 ± 0.10 | 74.3 ± 3.8 |
RTI-305 Norɑ-RTI-360/11y | Ethynyl | 1.24 ± 0.11 | 1.59 ± 0.2 | 21.8 ± 1.0 |
RTI-307 Norɑ-RTI-281/11z | Propynyl | 6.11 ± 0.67 | 3.16 ± 0.33 | 115.6 ± 5.1 |
RTI-309 Norɑ-11t | Vinyl | 1.73 ± 0.05 | 2.25 ± 0.17 | 14.9 ± 1.18 |
RTI-330 Norɑ-11s | Isopropyl | 310.2 ± 21 | 15.1 ± 0.97 | — |
RTI-353 | para-Et meta-I | 330.54 ± 17.12 | 0.69 ± 0.07 | 148.4 ± 9.15 |
ɑThe N-demethylated variant of (i.e. compound code-name after dash)
class="wikitable sortable"
|+N-demethylating various β,β p-HC-phenyltropanes !N-Me compound code# !para-X ![3H]Paroxetine ![3H]WIN 35,428 ![3H]Nisoxetine |
11 g→75f
|28.4 → 8.13 |55 → 49.9 |4,029 → 122 |
11t→75i
|9.5 → 2.25 |1.24 → 1.73 |78 → 14.9 |
11y→75n
|4.4 → 1.59 |1.2 → 1.24 |83.2 → 21.8 |
11r→75 g
|1-Propyl |70.4 → 26 |68.5 → 212 |3,920 → 532 |
11v→75k
|trans-propenyl |11.4 → 1.3 |5.29 → 28.6 |1,590 → 54 |
11w→75l
|cis-propenyl |7.09 → 1.15 |15 → 31.6 |2,800 → 147 |
11x→75 m
|28.4 → 6.2 |32.8 → 56.5 |2,480 → 89.7 |
11z→75o
|1-Propynyl |15.7 → 3.16 |2.37 → 6.11 |820 → 116 |
11s→75h
|i-Propyl |191 → 15.1 |597 → 310 |75,000 → ? |
11u→75j
|2-Propenyl |3.13 → 0.6 |14.4 → 23 |1,330? → 144 |
class="wikitable"
|+N-Demethylating phenyltropanes to find a NRI |
Isomer
!4′ !3′ !NE !DA !5HT |
---|
β,β
|Me |H |60 → 7.2 |1.7 → 0.84 |240 → 135 |
β,β
|F |H |835 → 18.8 |15.7 → 4.4 |760 → 68.6 |
β,β
|Cl |H |37 → 5.45 |1.12 → 0.62 |45 → 4.13 |
β,α
|Me |H |270 → 9 |10.2 → 33.6 |4250 → 500 |
β,α
|F |H |1200 → 9.8 |21 → 32.6 |5060 → 92.4 |
β,α
|Cl |H |60 → 5.41 |2.4 → 3.1 |998 → 53.3 |
β,α
|F |Me |148 → 4.23 |13.7 → 9.38 |1161 → 69.8 |
β,α
|Me |F |44.7 → 0.86 |7.38 → 9 |1150 → 97.4 |
"Interest in NET selective drugs continues as evidenced by the development of atomoxetine, manifaxine, and reboxetine as new NET selective compounds for treating ADHD and other CNS disorders such as depression" (FIC, et al. 2005).{{Cite journal
| last2 = Tyagi| first1 = F. | first2 = S.
| last4 = Kuhar
| last3 = Blough
| last5 = Navarro | first3 = B.
| last1 = Carroll | first4 = M. | first5 = H.
| title = Synthesis and monoamine transporter binding properties of 3α-(substituted phenyl)nortropane-2β-carboxylic acid methyl esters. Norepinephrine transporter selective compounds
| journal = Journal of Medicinal Chemistry
| volume = 48
| issue = 11
| pages = 3852–3857
| year = 2005
| pmid = 15916437
| doi = 10.1021/jm058164j
| url = https://figshare.com/articles/Synthesis_and_Monoamine_Transporter_Binding_Properties_of_3_Substituted_phenyl_nortropane_2_carboxylic_Acid_Methyl_Esters_Norepinephrine_Transporter_Selective_Compounds/3283483 }}
class="wikitable sortable"
! Structure ! Short Name ! Para-X ! DAT ! 5-HTT ! NET ! Selectivity ! Selectivity | |||||||
Norcocaine | H | 206 ± 29 | 127 ± 13 | 139 ± 9 | 0.6 | 0.7 | |
x100px | 75a | H | 30.8 ± 2.3 | 156 ± 8 | 84.5 ± 7.5 | 5.1 | 2.7 |
x100px | 75b | F | 4.39 ± 0.20 | 68.6 ± 2.0 | 18.8 ± 0.7 | 15.6 | 4.3 |
x100px | 75c | Cl | 0.62 ± 0.09 | 4.13 ± 0.62 | 5.45 ± 0.21 | 6.7 | 8.8 |
x100px | 75d | I | 0.69 ± 0.2 | 0.36 ± 0.05 | 7.54 ± 3.19 | 0.5 | 10.9 |
x110px | 75e | para-I & 2β-CO2CH(CH3)2 | 1.06 ± 0.12 | 3.59 ± 0.27 | 132 ± 5 | 3.4 | 124 |
x100px | 75f | C2H5 | 49.9 ± 7.3 | 8.13 ± 0.30 | 122 ± 12 | 0.2 | 2.4 |
x100px | 75g | n-C3H7 | 212 ± 17 | 26 ± 1.3 | 532 ± 8.1 | 0.1 | 2.5 |
x100px | 75h | CH(CH3)2 | 310 ± 21 | 15.1 ± 0.97| | |||
|0.05| | |||||||
x100px | 75i | CH=CH2 | 1.73 ± 0.05 | 2.25 ± 0.17 | 14.9 ± 1.18 | 1.3 | 8.6 |
x100px | 75j | C-CH3 CH2 | 23 ± 0.9 | 0.6 ± 0.06 | 144 ± 12 | 0.03 | 6.3 |
x100px | 75k | trans-CH=CHCH3 | 28.6 ± 3.1 | 1.3 ± 0.1 | 54 ± 16 | 0.04 | 1.9 |
x100px | 75l | cis-CH=CHCH3 | 31.6 ± 2.2 | 1.15 ± 0.1 | 147 ± 4.3 | 0.04 | 4.6 |
x100px | 75m | CH2CH=CH2 | 56.5 ± 56 | 6.2 ± 0.3 | 89.7 ± 9.6 | 0.1 | 1.6 |
x100px | 75n | CH≡CH | 1.24 ± 0.11 | 1.59 ± 0.2 | 21.8 ± 1.0 | 1.3 | 17.6 |
x100px | 75o | CH≡CCH3 | 6.11 ± 0.67 | 3.16 ± 0.33 | 116 ± 5.1 | 0.5 | 19.0 |
x110px | 75pɑ | 3,4-Cl2 | 0.66 ± 0.24 | 1.4b| | |||
|2.1| |
ɑThese values determined in Cynomolgus monkey caudate-putamen
bThe radioligand used for 5-HTT was [3H]citalopram
class="wikitable sortable"
|+2β-Propanoyl-N-norphenyltropanes ! Compound Structure ! Short Name ! DAT ! 5-HTT ! NET ! Selectivity ! Selectivity | ||||||
x100px | 79a | 0.07 ± 0.01 | 0.22 ± 0.16 | 2.0 ± 0.09 | 3.1 | 28.6 |
x100px | 79b | 4.7 ± 0.58 | 19 ± 1.4 | 5.5 ± 2.0 | 4.0 | 1.2 |
x100px | 79c | 380 ± 110 | 5.3 ± 1.0 | 3400 ± 270 | 0.01 | 8.9 |
x100px | 79d | 190 ± 17 | 150 ± 50 | 5100 ± 220 | 0.8 | 26.8 |
x100px | 79e | 490 ± 120 | 85 ± 16 | 4300 ± 1100 | 0.1 | 8.8 |
x100px | 79f | 1.5 ± 1.1 | 0.32 ± 0.06 | 10.9 ± 1.5 | 0.2 | 7.3 |
x100px | 79g | 16 ± 4.9 | 0.11 ± 0.02 | 94 ± 18 | 0.07 | 5.9 |
==Paroxetine homologues==
See the N-methyl paroxetine homologues
cf. di-aryl phenyltropanes for another SSRI approximated hybrid: the fluoxetine based homologue of the phenyltropane class.
class="wikitable sortable"
|+2-(3,4-(Methylenedioxy)phenoxy)methyl-norphenyltropane binding potencies ! Compound Structure ! Short Name ! Stereochemistry ! DAT ! 5-HTT ! NET ! Selectivity ! Selectivity | |||||||
x130px | Paroxetine | | ||||||
|623 ± 25 | 0.28 ± 0.02 | 535 ± 15 | 0.0004 | 0.8 | |||
x130px | R-81a | 2β,3β | 835 ± 90 | 480 ± 21 | 37400 ± 1400 | 0.6 | 44.8 |
x130px | R-81b | 2α,3β | 142 ± 13 | 90 ± 3.4 | 2500 ± 250 | 0.6 | 17.6 |
x180px | R-81c | 2β,3α | 3.86 ± 0.2 | 5.62 ± 0.2 | 14.4 ± 1.3 | 1.4 | 3.7 |
x130px | S-81d | 2β,3β | 1210 ± 33 | 424 ± 15 | 17300 ± 1800 | 0.3 | 14.3 |
x130px | S-81e | 2α,3β | 27.6 ± 2.4 | 55.8 ± 5.73 | 1690 ± 150 | 2.0 | 61.2 |
x180px | S-81f | 2β,3α | 407 ± 33 | 19 ± 1.8 | 1990 ± 176 | 0.05 | 4.9 |
= ''N''-replaced (S,O,C) =
{{multiple image
| align = center
| perrow = 2
| image1 = Phenyltropane R-97a.svg
| width1 = 220
| caption1 = R-97a (above) & S-97b (below), both examples of interim. synth. prod. in the R/S-90 & 91 series of phenyltropanes; showing the decay of the benzene structure during the synthetic process preceding the creation of like-series of PTs.
| image3 = Phenyltropane S-97b.svg
| width3 = 220
| image2 = Tropoxane.png
| width2 = 300
| image4 = Thia.png
| width4 = 400
| image5 = 10,10-dimethyl-4-((1R,5S)-8-methyl-8-azabicyclo(3.2.1)oct-2-ene-2-carbonyl)-3λ⁶-thia-4-azatricyclo(5.2.1.0¹,⁵)decane-3,3-dione.svg
| width5 = 220
| caption5 = Mid-synth stage in similar compound preparation as like to above.
| image6 = Meltzer.png
| width6 = 400
}}
The eight position nitrogen has been found to not be an exclusively necessary functional anchor for binding at the MAT for phenyltropanes and related compounds. Sulfurs, oxygens, and even the removal of any heteroatom, leaving only the carbon skeleton of the structure at the bridged position, still show distinct affinity for the monoamine transporter cocaine-target site and continue to form an ionic bond with a measurable degree of reasonable efficacy.
class="wikitable"
! Compound ! X ! 2 Group ! config ! 8 | DA | 5-HT | NE | ||||
Tropoxane | Cl,Cl | CO2Me | (racemic) β,β | O | 3.3 | 6.5 | No data |
O-4210{{Cite journal|pmid=21146984|pmc=3015105|year=2011|last1=Purushotham|first1=M|title=The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo3.2.1octanes|journal=Bioorganic & Medicinal Chemistry Letters|volume=21|issue=1|pages=48–51|last2=Sheri|first2=A|last3=Pham-Huu|first3=D. P.|last4=Madras|first4=B. K.|last5=Janowsky|first5=A|last6=Meltzer|first6=P. C.|doi=10.1016/j.bmcl.2010.11.076}} | p-F | 3-methyl-5-isoxazole | β,β | S | 7.0 | >1000 | No data |
==8-oxa bridgehead replacements==
class="wikitable sortable"
|+8-Oxanortropanes, binding inhibition using monkey caudate-putamen ! Structure ! Compound # ! Para- ! DAT (IC50 nM) ! 5-HTT (IC50 nM) ! Selectivity | |||||
120px | R/S-90a | H | >1000 | >1000| | |
140px | R/S-90b | F | 546 | 2580 | 4.7 |
140px | R/S-90c | Cl | 10 | 107 | 10.7 |
140px | R/S-90d | Br | 22 | 30 | 1.4 |
140px | R/S-90e | I | 7 | 12 | 1.7 |
140px | R/S-90f | 3,4-Cl2 | 3.35 | 6.52 | 1.9 |
140px | R-90g | 3,4-Cl2 | 3.27 | 4.67 | 1.4 |
140px | S-90h | 3,4-Cl2 | 47 | 58 | 1.2 |
90px | R/S-91a | H | 1990 | 11440 | 5.7 |
90px | R/S-91b | F | >1000 | >10000| | |
90px | R/S-91c | Cl | 28.5 | 816 | 28.6 |
90px | R/S-91d | Br | 9 | 276 | 30.7 |
90px | R/S-91e | I | 42 | 72 | 1.7 |
100px | R/S-91f | 3,4-Cl2 | 3.08 | 64.5 | 20.9 |
100px | R-91g | 3,4-Cl2 | 2.34 | 31 | 13.2 |
100px | S-91h | 3,4-Cl2 | 56 | 2860 | 51.1 |
==8-carba bridgehead replacements==
class="wikitable sortable"
|+8-carba 3-Aryl bicyclo ! Structure ! Compound # ! DAT (IC50 nM) ! 5-HTT (IC50 nM) ! Selectivity | ||||
140px | R/S-98a | 7.1 ± 1.7 | 5160 ± 580 | 726 |
140px | R/S-98b | 9.6 ± 1.8 | 33.4 ± 0.6 | 3.5 |
100px | R/S-98c | 14.3 ± 1.1 | 180 ± 65 | 12.6 |
= ''N''-alkyl =
File:RTI-242 structure.png
File:Altropane.svg
File:Ioflupane.png
class="wikitable"
!Compound!!X!!2 Group!!config!!8!! DAT!!SERT!!NET | |||||||
FP-β-CPPIT | Cl | 3′-phenylisoxazol-5′-yl | β,β | NCH2CH2CH2F | - | - | - |
FE-β-CPPIT | Cl | (3′-phenylisoxazol-5′-yl) | β,β | NCH2CH2F | - | - | - |
Altropane (IACFT) | F | CO2Me | β,β | NCH2CH=CHF | - | - | - |
FECNT{{cite journal|last1=Wu|first1=Xiaoai|last2=Cai|first2=Huawei|last3=Ge|first3=Ran|last4=Li|first4=Lin|last5=Jia|first5=Zhiyun|title=Recent Progress of Imaging Agents for Parkinson's Disease|journal=Current Neuropharmacology|volume=12|issue=6|year=2015|pages=551–563|issn=1570-159X|doi=10.2174/1570159X13666141204221238|pmc=4428027|pmid=25977680}} | I | CO2Me | β,β | NCH2CH2F | - | - | - |
RTI-310 {{US patent|5736123}} | I | CO2Me | β,β | N-Prn | 1.17 | - | - |
RTI-311 | I | CO2Me | β,β | NCH2CH=CH2 | 1.79 | - | - |
RTI-312 {{US patent|5736123}} | I | CO2Me | β,β | NBun | 0.76 | - | - |
RTI-313 {{US patent|5736123}} | I | CO2Me | β,β | NCH2CH2CH2F | 1.67 | - | - |
Ioflupane (FP-CIT) | 123I | CO2Me | β,β | NCH2CH2CH2F | - | - | - |
PE2I | Me | CO2Me | β,β | NCH2CH=CHI | - | - | - |
RTI-251 | Cl | CO2Me | β,β | NCH2CO2Et | 1.93 | 10.1 | 114 |
RTI-252 | Cl | CO2Me | β,β | NCH2CH2CO2Et | 2.56 | 35.2 | 125 |
RTI-242 | Cl | colspan=3| β,β (bridged) -C(O)CH(CO2Me)CH2N | 7.67 | 227 | 510 |
Bi- and tri-cyclic aza compounds and their uses.{{US patent|6150376}}{{Cite patent|country=WO|number=0007994|title=Novel bi- and tri-cyclic aza compounds and their uses|pubdate=2000-02-17|assign=Georgetown University|inventor1-last=Kozikowski|inventor1-first=Alan P.|inventor2-last=Smith|inventor2-first=Miles P.}}
class="wikitable sortable"
|+N-substituted 3β-phenylnortropanes ! Structure ! Short Name ! Nitrogen side-chain ! DAT ! 5-HTT ! NET ! Selectivity ! Selectivity | |||||||
Cocaine | H | 350 ± 80 | >10000 | >30000 | >28.6| | ||
GBR 12909 | | |||||||
|0.06 ± 0.02 | 52.8 ± 4.4 | >20000 | 880| | ||||
WIN 35428 11b | H | 14.7 ± 2.9 | 181 ± 21 | 635 ± 110 | 12.3 | 43.2 | |
RTI-55 11e | H | 1.40 ± 0.20 | 0.46 ± 0.06 | 2.80 ± 0.40 | 0.3 | 2 | |
150px | 82a | CH2CH=CH2 | 22.6 ± 2.9ɑ| | ||||
150px | 82b | CH2CH2CH3 | 43.0 ± 17.7ɑ| | ||||
160px | 82c | CH2C6H5 | 58.9 ± 1.65b | 1073c| | |||
|18.2| | |||||||
200px | 82d | (CH2)3C6H5 | 1.4 ± 0.2b | 133 ± 7c| | |||
|95.0| | |||||||
210px | 82e | (CH2)5C6H5 | 3.4 ± 0.83b | 49.9 ± 10.2c| | |||
|14.7| | |||||||
160px | 83a | CH2CH2CH2F | 1.20 ± 0.29 | 48.7 ± 8.4 | 10000 | 40.6 | 8333 |
160px | 83b | CH2CH2F | 4.40 ± 0.35 | 21.7 ± 8.3 | >10000 | 4.9| | |
160px | 84a | CH2CH2CH2F | 3.50 ± 0.39 | 0.110 ± 0.02 | 63.0 ± 4.0 | 0.03 | 18 |
160px | 84b | CH2CH2F | 4.00 ± 0.73 | 0.140 ± 0.02 | 93.0 ± 17.0 | 0.03 | 23.2 |
160px | 84c | CH2CHF2 | 15.1 ± 3.7 | 9.6 ± 1.5 | >5000 | 0.6| | |
170px | 84d | CH2CH2CH2Cl | 3.10 ± 0.57 | 0.32 ± 0.06 | 96.0 ± 29.0 | 0.1 | 31.0 |
170px | 84e | CH2CH2CH2Br | 2.56 ± 0.57 | 0.35 ± 0.08 | 164 ± 47 | 0.1 | 64.1 |
170px | 84f | CH2CH2CH2I | 38.9 ± 6.3 | 8.84 ± 0.53 | 5000 | 0.2 | 128 |
170px | 84g | CH2...methylcyclopropane | 4.30 ± 0.87 | 1.30 ± 0.25 | 198 ± 9.6 | 0.3 | 46.0 |
180px | 84h | CH2CH2CH2OH | 5.39 ± 0.21 | 2.50 ± 0.20 | 217 ± 19 | 0.5 | 40.2 |
200px | 84i | CH2CH2(OCH3)2 | 6.80 ± 1.10 | 1.69 ± 0.09 | 110 ± 7.7 | 0.2 | 16.2 |
180px | 84j | CH2CO2CH3 | 11.9 ± 1.4 | 0.81 ± 0.10 | 29.1 ± 1.0 | 0.07 | 2.4 |
185px | 84k | CH2CON(CH3)2 | 12.2 ± 3.8 | 6.40 ± 1.70 | 522 ± 145 | 0.5 | 42.8 |
200px | 84l | CH2CH2CH2OMs | 36.3 ± 2.1 | 17.3 ± 1.2 | 5000 | 0.5 | 138 |
170px | 84m | COCH(CH3)2 | 2100 ± 140 | 102 ± 23 | >10000 | 0.05| | |
210px | 84n | (CH2)2Pht | 4.23 ± 0.48 | 0.84 ± 0.02 | 441 ± 66.0 | 0.2 | 104 |
210px | 84o | (CH2)3Pht | 9.10 ± 1.10 | 0.59 ± 0.07 | 74.0 ± 11.6 | 0.06 | 8.1 |
230px | 84p | (CH2)4Pht | 2.38 ± 0.22 | 0.21 ± 0.02 | 190 ± 18.0 | 0.09 | 79.8 |
230px | 84q | (CH2)5Pht | 2.40 ± 0.17 | 0.34 ± 0.03 | 60.0 ± 3.10 | 0.1 | 25.0 |
270px | 84r | (CH2)8Pht | 2.98 ± 0.30 | 0.20 ± 0.02 | 75.0 ± 3.6 | 0.07 | 25.2 |
170px | 84sd | CH2CH=CH-CH3 | 15 ± 1 | 75 ± 5 | 400 ± 80 | 5.0 | 26.7 |
170px | 84td | CH2C(Br)=CH2 | 30 ± 5 | 200 ± 40 | >1000 | 6.7| | |
170px | 84ud | CH2CH=CH2I(E) | 30 ± 5 | 960 ± 60 | 295 ± 33 | 32.0 | 9.8 |
170px | 84vd | CH2C≡CH | 14 ± 1 | 100 ± 30 | >1000 | 7.1| | |
170px | 84wd | CH2C6H5 | 42 ± 12 | 100 ± 17 | 600 ± 100 | 2.4 | 14.3 |
170px | 84xd | CH2C6H4-2-CH3 | 93 ± 19 | 225 ± 40 | >1000 | 2.4| | |
160px | 85ad | para-H | 113 ± 41 | 100 ± 20 | >1000 | 0.9| | |
170px | 85bd | para-Cl, meta-Cl | 29 ± 4 | 50 ± 6 | 500 ± 120 | 1.7 | 17.2 |
170px | 85cd | para-Me | 17 ± 7 | 500 ± 30 | >1000 | 29.4| | |
180px | 85dd | para-CH(CH3)2 | 500 ± 120 | 450 ± 80 | >1000 | 0.9| | |
190px | 85ed | para-n-C3H7 | 500 ± 100 | 300 ± 12 | 750 ± 160 | 0.6 | 1.5 |
- ɑIC50 for displacement of [3H]cocaine. IC50 for cocaine = 67.8 ± 8.7 (nM)
- bIC50 values for displacement of [3H]WIN 35428
- cIC50 values for displacement of [3H]citalopram
- dThe standard Ki value for the displacement of [3H]GBR 12935, [3H]paroxetine, and [3H]nisoxetine were 27 ± 2, 3 ± 0.2, and 80 ± 28 nM, respectively, for these experiments
class="wikitable sortable"
|+3β-(4-alkylthiophenyl)nortropanes ! Structure 150px ! Compound ! R1 ! R2 ! Inhibition of [3H]WIN 35,428 ! Inhibition of [3H]Paroxetine ! Inhibition of [3H]Nisoxetine ! NET/DAT ! NET/5-HTT | ||||||||
rowspan=3|See 7a—7h table | ||||||||
7a | CH3 | CH3 | 9 ± 3 | 0.7 ± 0.2 | 220 ± 10 | 24 | 314 | |
7b | C2H5 | CH3 | 232 ± 34 | 4.5 ± 0.5 | 1170 ± 300 | 5 | 260 | |
160px | 8a | CH3 | H | 28 ± 6 | 0.19 ± 0.01 | 21 ± 6 | 0.8 | 110 |
170px | 8b | C2H5 | H | 177 ± 62 | 1.26 ± 0.05 | 118 ± 13 | 0.7 | 94 |
210px | 9a | CH3 | FCH2CH2CH2 | 112 ± 2 | 3 ± 1 | 960 ± 100 | 9 | 320 |
215px | 9b | C2H5 | FCH2CH2CH2 | 1,200 ± 200 | 27 ± 2 | >2,000 | 2 | 74 |
200px | 10a | CH3 | CH2=CH2CH2 | 71 ± 25 | 5.5 ± 0.8 | 2,000 ± 500 | 28 | 364 |
205px | 10b | C2H5 | CH2=CH2CH2 | 1,100 ± 100 | 47 ± 3 | >2,000 | 2 | 43 |
200px | 11a | CH3 | CH3CH2CH2 | 74 ± 20 | 5.7 ± 0.6 | 1,200 ± 140 | 16 | 211 |
205px | 11b | C2H5 | CH3CH2CH2 | 900 ± 300 | 49 ± 6 | >2,000 | 2 | 41 |
= Bridged ''N''-constrained phenyltropanes (fused/tethered) =
== ''p''-methyl aryl front & back ''N''-bridged phenyltropanes ==
{{US patent|6150376}}
{{multiple image|total_width=660|perrow=2|align=center
|image1=Alt2D-bridged-phenyltropane-no42a.png|width1=325|caption1=Alternate 2D rendering of compound "42a" (from among the above 'bridged' phenyltropanes) to elucidate the potential overlaying structure of the place inhabited by the constrained nitrogen. Compare JNJ-7925476, tametraline and similar compounds.
|image2=RTI-4229-242.png|width2=325|caption2=RTI-242
}}
{{sort-under}}
class="wikitable sortable sort-under"
|+Activity at monoamine transporters: Binding Affinities & MAT Inhibition of Bridged Phenyltropanes Ki (nM) !Compound # !2β=R ![3H]Mazindol ![3H]DA ![3H]5-HT ![3H]NE !selectivity | ||||||
cocaine | CO2CH3 | 375 ± 68 | 423 ± 147 | 155 ± 40 | 83.3 ± 1.5 | 0.4 |
(–)-40 (–)-128 | 54.3 ± 10.2 | 60.3 ± 0.4 | 1.76 ± 0.23 | 5.24 ± 0.07 | 0.03 | |
(+)-40 (+)-128 | 79 ± 19 | 114 ± 28 | 1.48 ± 0.07 | 4.62 ± 0.31 | 0.01 | |
(±)-40 (±)-128 | 61.7 ± 8.5 | 60.3 ± 0.4 | 2.32 ± 0.23 | 2.69 ± 0.12 | 0.04 | |
29β | 620 | 1420 | 8030 | — | — | |
30β | 186 | 492 | 97.7 | — | — | |
31β | 47.0 | 211 | 28.5 | — | — | |
29α | 4140 | 20100 | 3920 | — | — | |
30α | 3960 | 8850 | 696 | 1150 | — | |
45 129 | 6.86 ± 0.43 | 24.0 ± 1.3 | 1.77 ± 0.04 | 1.06 ± 0.03 | 0.07 | |
42a 131a | n-Bu | 4.00 ± 0.07 | 2.23 ± 0.12 | 14.0 ± 0.6 | 2.99 ± 0.17 | 6.3 |
41a 130a | n-Bu | 17.2 ± 1.13 | 10.2 ± 1.4 | 78.9 ± 0.9 | 15.0 ± 0.4 | 7.8 |
42b 131b | Et | 3.61 ± 0.43 | 11.3 ± 1.1 | 25.7 ± 4.3 | 4.43 ± 0.01 | 2.3 |
50a 133a | n-Bu | 149 ± 6 | 149 ± 2 | 810 ± 80 | 51.7 ± 12 | 5.4 |
49a 132a | n-Bu | 13.7 ± 0.8 | 14.2 ± 0.1 | 618 ± 87 | 3.84 ± 0.35 | 43.5 |
(–)-4 | 10500 | 16500 | 1890 | 70900 | — | |
(+)-4 | 18500 | 27600 | 4630 | 38300 | — | |
(–)-5 | 9740 | 9050 | 11900 | 4650 | — | |
(+)-5 | 6770 | 10500 | 25100 | 4530 | — | |
RTI-4229/Coc-242 | N8/2β-C(O)CH(CO2Me)CH2N para-chloro | — | 7.67 ± 0.31ɑ | 226.54 ± 27.37b | 510.1 ± 51.4c | — |
- ɑValue for displacement of [3H]WIN 35,428 binding @ DAT
- bValue for displacement of [3H]paroxetine binding to SERT
- cValue for displacement of [3H]nisoxetine from NET
Fused tropane-derivatives as neurotransmitter reuptake inhibitors. Singh notes that all bridged derivatives tested displayed 2.5—104 fold higher DAT affinity than cocaine. The ones 2.8—190 fold more potent at DAT also had increased potency at the other two MAT sites (NET & SERT); NET having 1.6—78× increased activity. (+)-128 additionally exhibited 100× greater potency @ SERT, whereas 132a & 133a had 4–5.2× weaker 5-HTT (i.e. SERT) activity. Front-bridged (e.g. 128 & 129) had a better 5-HT/DA reuptake ratio in favor of SERT, while the back-bridged (e.g. 130–133) preferred placement with DAT interaction.
{{US patent|5998405}}
== 3,4-Cl<sub>2</sub> aryl front-bridged phenyltropanes ==
File:Fused Tropane.png A/S, Scheel-Krüger et al. {{US patent|5998405}}]]
class="wikitable"
! Code!!Compound!!DA (μM)!!NE (μM)!!5-HT (μM) | ||||
1 | (1 S,2S,4S,7R)-2-(3,4-Dichloro- phenyl)-8-azatricyclo[5.4.0.04,8]- undecan-11 -one O-methyl-oxime | 0.012 | 0.0020 | 0.0033 |
2 | (1 S,2S,4S,7R)-2-(3,4-Dichloro- phenyl)-8-azatricyclo[5.4.0.04,8]- undecan-11-one | 0.18 | 0.035 | 0.0075 |
3 | (1 S,3S,4S,8R)-3-(3,4-Dichloro-phenyl)-7-azatricyclo[5.3.0.04,8]- decan-5-one O-methyl-oxime | 0.0160 | 0.0009 | 0.0032 |
4 | (1 S,2S,4S,7R)-2-(3,4-Dichloro-phenyl)-8-azatricyclo[5.4.0.04,8]- undecan-11-ol | 0.0750 | 0.0041 | 0.0028 |
5 | (1 S,3S,4S,8R)-3-(3,4-Dichloro-phenyl)-7-azatricyclo[5.3.0.04,8]- decan-5-one | 0.12 | 0.0052 | 0.0026 |
6 | (1 S,3S,4S,8R)-3-(3,4-Dichloro- phenyl)-7-azatricyclo[5.3.0.04,8]-decan-5-ol | 0.25 | 0.0074 | 0.0018 |
7 | (1S,3S,4S,8R)-3- (3,4-Dichloro- phenyl)-7-azatricyclo[5.3.0.04,8]dec- 5-yl acetate | 0.21 | 0.0061 | 0.0075 |
8 | (1S,3S,4S,8R)-3-(3,4-Dichlorophenyl)-5-methoxy-7- azatricyclo[5.3.0.04,8]decane | 0.022 | 0.0014 | 0.0001 |
- 1-Chloroethyl chloroformate is used to remove N-methyl of trans-aryltropanes.
- 2° amine is reacted with Br(CH2)nCO2Et.
- Base used to abstract proton α- to CO2Et group and complete the tricyclic ring closure step (Dieckmann cyclization).
To make a different type of analog (see Kozikowski patent above)
- Remove N-Me
- Add ɣ-bromo-chloropropane
- Allow for cyclization with K2CO3 base and KI cat.
==C2 + C3 (side-chain) fused (carboxylate & benzene conjoined)==
==C3 to 1′ + 2′ (''ortho'') tropane locant dual arene bridged==
Parent compound of a series of spirocyclic cocaine benzoyl linkage modification analogs created by Suzuki coupling method of ortho-substituted arylboronic acids and an enol-triflate derived from cocaine; which technically has the three methylene length of cocaine analogues as well as the single length which defines the phenyltropane series. Note that the carbomethoxyl group is (due to constraints in synthetic processes used in the creation of this compound) alpha configured; which is not the usual, most prevalent, conformation favored for the PT cocaine-receptor binding pocket of most such sub-type of chemicals. The above and below depictions show attested compounds synthesized, additionally with variations upon the Endo–exo isomerism of their structures.{{cite journal | last1 = Sakamuri | first1 = Sukumar |display-authors=etal | year = 2000 | title = Synthesis of novel spirocyclic cocaine analogs using the Suzuki coupling | journal = Tetrahedron Letters | volume = 41 | issue = 13| pages = 2055–2058 | doi = 10.1016/S0040-4039(00)00113-1 }}
Cycloalkane-ring alterations of the tropane ring system
= Azanonane (outer ring extended) =
3-Phenyl-9-azabicyclo[3.3.1]nonane derivatives
To better elucidate the binding requirements at MAT, the methylene unit on the tropane was extended by one to create the azanonane analogs.{{efn| ←[https://www.erowid.org/archive/rhodium/pdf/cocaineanalogs.pdf#43 Page #967 (43rd page of article)] 2nd column}} Which are the beginning of classes of modifications that start to become effected by the concerns & influences of macrocyclic stereocontrol.
Despite the loosened flexibility of the ring system, nitrogen constrained variants (such as were created to make the bridged class of phenyltropanes) which might better fit the rigid placement necessary to suit the spatial requirements needed in the binding pocket were not synthesized. Though front-bridged types were synthesized for the piperidine homologues: the trend of equal values for either isomers of that type followed the opposing trend of a smaller and lessened plasticity of the molecule to contend with a rationale for further constraining the pharmacophore within that scope. Instead such findings lend credence to the potential for the efficacy of fusing the nitrogen on an enlarged tropane, as like upon the compounds given below.
class="wikitable sortable"
|+[3.3.1]azanonane analogues ! Structure ! Compound # ! Ki (nM) | ||
File:Kokain - Cocaine.svg | Cocaine | 32 ± 5 390 ± 220 |
File:WIN 35,065-2.svg | WIN 35065-2 | 33 ± 17 310 ± 220 |
File:Cocaine analog 146a.svg | 146a | 4600 ± 510 |
File:Cocaine analog 146b.svg | 146b | 5730 ± 570 |
File:Cocaine analog 146c.svg | 146c | 3450 ± 310 |
File:Cocaine analog 146d.svg | 146d | 3470 ± 350 |
File:Cocaine analog 147.svg | 147 | 13900 ± 2010 |
= Azabornane (outer ring contracted) =
3-Phenyl-7-azabicyclo[2.2.1]heptane derivatives
Ring-contracted analogs of phenyltropanes did not permit sufficient penetration of the phenyl into the target binding site on MAT for an affinity in the efficacious range. The distance from the nitrogen to the phenyl centroid for 155a was 4.2 and 155c was 5.0 Å, respectively. (Whereas troparil was 5.6 & compound 20a 5.5 angstroms). However piperidine homologues (discussed below) had comparable potencies.{{efn| ←[https://www.erowid.org/archive/rhodium/pdf/cocaineanalogs.pdf#43 Page #967 (43rd page of article)] 2nd column}}
File:2-exo-phenyl-7-azabicyclo(2-2-1)heptane.png releaser of MAT & VMAT, yet similar to phenyltropanes (that usually are only re-uptake ligands)[http://www.ingentaconnect.com/content/els/00404039/1995/00000036/00000039/art01414 exo-2-Phenyl-7-azabicyclo
Azabornanes with longer substitutions at the 3β-position (benzoyloxys alkylphenyls, carbamoyls etc.) or with the nitrogen in the position it would be on the piperidine homologues (i.e. arrangements of differing locations for the nitrogens being either distal or proximal within the terms required to facilitate the framework of the compound to a correlative proportion, functional for the given moiety), were not synthesized, despite conclusions that the nitrogen to phenyl length was the issue at variance enough to be the interfering factor for the proper binding of the compressed topology of the azabornane. Carroll, however, has listed benzoyloxy azabornanes in patents.
class="wikitable sortable"
|+[2.2.1]azabornane analogues ! Structure ! Compound # ! Ki (nM) | ||
File:Kokain - Cocaine.svg | Cocaine | 32 ± 5 390 ± 220 |
File:WIN 35,065-2.svg | WIN 35065-2 | 33 ± 17 310 ± 220 |
File:Cocaine analog 155a.svg | 155a | 60,400 ± 4,800 |
File:Cocaine analog 155b.svg File:Cocaine analog 155b alt.svg | 155b | 96,500 ± 42 |
File:Cocaine analog 155c.svg | 155c | 5,620 ± 390 |
File:Cocaine analog 155d.svg | 155d | 18,900 ± 1,700 |
= Piperidine [[Homologous series|homologues]] (inner two-carbon bridge excised) =
Piperidine homologues had comparable affinity & potency spreads to their respective phenyltropane analogues. Without as much of a discrepancy between the differing isomers of the piperidine class with respect to affinity and binding values as had in the phenyltropanes.
== distal-nitrogen 'dimethylamine' (piperidine-like cyclohexyl homologues of phenyltropanes) ==
Radiolabeled
File:LBT-999.svg, a radio-ligand.]]
File:N-3-iodoprop-(2E)-ene-2β-carbomethoxy-3β-(4′-chlorophenyl)tropane.png|IPT (N-3-iodoprop-(2E)-ene-2β-carbomethoxy-3β-(4′-chlorophenyl)tropane), can be radiolabeled with 123I or 125I and used as a ligand to map several MATs
File:N-4-Fluorobut-2-yn-1-yl-2β-carbomethoxy-3β-phenyltropane.png|N-4-Fluorobut-2-yn-1-yl-2β-carbomethoxy-3β-phenyltropane (PR04.MZ) often radiolabeled.{{cite journal | pmid = 22073420 | title=N-4-Fluorobut-2-yn-1-yl-2β-carbo-[11C]methoxy-3β-phenyltropane | last1 = Leung | first1 = K | year=2004}}{{cite journal | pmid = 2207342 | volume=61 | issue=2–3 | title=Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen | journal=Blut | pages=55–9 | last1 = Stenzinger | first1 = W | last2 = Blömker | first2 = A | last3 = Hiddemann | first3 = W | last4 = de Loo | first4 = J | doi=10.1007/bf02076700 | year=1990| s2cid=25860357 }}
File:JHC 1-64.svg|JHC1-64.{{cite journal| pmc=5511133 | pmid=28710426 | doi=10.1038/s41598-017-05637-x | bibcode=2017NatSR...7.5399M | volume=7 | issue=1 | title=Targeting of dopamine transporter to filopodia requires an outward-facing conformation of the transporter | year=2017 | journal=Sci Rep | page=5399 | last1 = Ma | first1 = S | last2 = Cheng | first2 = MH | last3 = Guthrie | first3 = DA | last4 = Newman | first4 = AH | last5 = Bahar | first5 = I | last6 = Sorkin | first6 = A}} A fluorescent analog, similar in its long chain off of the nitrogen bridge similar to the transition metal phenyltropane types.
= Transition metal complexes =
These compounds include transition metals in their heteroatomic conformation, unlike non-radiolabel intended chelates where their element is chosen for intrinsic affectation to binding and function, these are tagged on by a "tail" (or similar) with a sufficient spacer to remain separated from known binding properties and instead are meant to add radioactivity enough to be easily tracked via observation methods that utilize radioactivity. As for anomalies of binding within the spectrum of the under-written kinds just mentioned: other factors not otherwise considered to account for its relatively lower potency, "compound 89c" is posited to protrude forward at the aryl place on its moiety toward the MAT ligand acceptor site in a manner detrimental to its efficacy. That is considered due to the steric bulk of the eight-position "tail" chelate substituted constituent, overreaching the means by which it was intended to be isolated from binding factors upon a tail, and ultimately nonetheless, interfering with its ability to bind. However, to broach this discrepancy, decreasing of the nitrogen tether at the eight position by a single methylene unit (89d) was shown to bring the potency of the analogous compound to the expected, substantially higher, potency: The N-methyl analog of 89c having an IC50 of 1.09 ± 0.02 @ DAT & 2.47 ± 0.14 nM @ SERT; making 89c upwards of thirty-three times weaker at those MAT uptake sites.{{efn| ←[https://www.erowid.org/archive/rhodium/pdf/cocaineanalogs.pdf#31 Page #955 (31st page of article)] 1st (left) column, 2nd ¶}}
class="wikitable sortable"
|+"Transition metal" chelated phenyltropanes ! Structure ! Compound # ! X = para- / 4′- ! Configuration ! DAT (IC50 nM) ! 5-HTT (IC50 nM) ! Selectivity | ||||||
File:Phenyltropane 11b - WIN 35428.svg | WIN 35428 | F | - | 11.0 ± 1.0 | 160 ± 20 | 14.5 |
+2β-chelated phenyltropanes | ||||||
---|---|---|---|---|---|---|
File:Cocaine analog 73 - TRODAT-1.svg | 73 TRODAT-1ɑ | Cl | - | R=13.9, S=8.42b| | ||
File:Cocaine analog 74 - TROTEC-1.svg | 74 TROTEC-1 | F | - | high affinity site = 0.15 ± 0.04c low affinity site = 20.3 ± 16.1c| | ||
colspan=7 style="text-align:center;" |N-chelated phenyltropanes | ||||||
File:Cocaine analog 89a.svg | 89a | F | 2β | 5.99 ± 0.81 | 124 ± 17 | 20.7 |
File:Cocaine analog 89b.svg | 89b | F | 2α | 2960 ± 157 | 5020 ± 1880 | 1.7 |
File:Cocaine analog 89c.svg | 89c | 3,4-Cl2 | 2β | 37.2 ± 3.4 | 264 ± 16 | 7.1 |
File:Cocaine analog 89d.svg | 89d | Cl | - | 0.31 ± 0.03d | - | |
- ɑIUPAC:
[2-[[2-[[[3-(4-chlorophenyl)-7-methyl-8-azabicyclo[3,2,1]oct-2-yl]methyl]-(2-mercaptoethyl)amino]ethyl]amino]ethanethiolato-(3—)-N2, N2′, S2, S2′]oxo-[1R-(exo, exo)]-[99mTc]technetium - bR- & S- isomer values are Ki (nM) for displacement of
[ 125I] IPT with technetium-99m replaced by rhenium - cIC50 (nM) values for displacement of
[ 3H] WIN 35428 with ligand tricarbonyltechnetium replaced with rhenium. (IC50 for WIN 35428 were 2.62 ± 1.06 @ high affinity binding & 139 ± 72 @ low affinity binding sites) - dKi value for displacement of [125I]IPT radioligand.
{{clear}}
Select annotations of above
Phenyltropanes can be grouped by "N substitution" "Stereochemistry" "2-substitution" & by the nature of the 3-phenyl group substituent X.
Often this has dramatic effects on selectivity, potency, and duration, also toxicity, since phenyltropanes are highly versatile. For more examples of interesting phenyltropanes, see some of the more recent patents, e.g. {{US Patent|6329520}}, {{US Patent|7011813}}, {{US Patent|6531483}}, and {{US Patent|7291737}}.
Potency in vitro should not be confused with the actual dosage, as pharmacokinetic factors can have a dramatic influence on what proportion of an administered dose actually gets to the target binding sites in the brain, and so a drug that is very potent at binding to the target may nevertheless have only moderate potency in vivo. For example, RTI-336 requires a higher dosage than cocaine. Accordingly, the active dosage of RTI-386 is exceedingly poor despite the relatively high ex vivo DAT binding affinity.
Sister substances
Many molecular drug structures have exceedingly similar pharmarcology to phenyltropanes, yet by certain technicalities do not fit the phenyltropane moniker. These are namely classes of dopaminergic cocaine analogues that are in the piperidine class (a category that includes methylphenidate) or benztropine class (such as Difluoropine: which is extremely close to fitting the criteria of being a phenyltropane.) Whereas other potent DRIs are far removed from being in the phenyltropane structural family, such as Benocyclidine or Vanoxerine.
Most any variant with a tropane locant—3-β (or α) connecting linkage differing from, e.g. longer than, a single methylene unit (i.e. "phenyl"), including alkylphenyls (see the styrene analog, first image given in example below) is more correctly a "cocaine analogue" proper, and not a phenyltropane. Especially if this linkage imparts a sodium channel blocker functionality to the molecule.
See also
References
= Citations =
{{Reflist}}
External links
- [http://www.wipo.int/pctdb/en/wo.jsp?wo=2003099783&IA=WO2003099783&DISPLAY=DESC U. S. Provisional Patent Application listing examples of compounds that are tropanes for prospective use in research]
- [http://www.emory.edu/ACAD_EXCHANGE/2001/octnov/kuharqa.html Article on cocaine analogue research] {{Webarchive|url=https://web.archive.org/web/20060922070754/http://www.emory.edu/ACAD_EXCHANGE/2001/octnov/kuharqa.html |date=2006-09-22 }}
{{Phenyltropanes}}
{{Chemical classes of psychoactive drugs}}
Category:Chemical classes of psychoactive drugs